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Abstract
Cytochrome P450s are versatile biocatalysts with the ability to accept a vast range
of substrates. However, to enable their high potential they are in need of electrons.
Those are delivered via complex electron transfer chains including an electron donor
(NAD(P)H) and one or two transfer proteins. Transfer proteins are exchangeable
from different organisms and work in various combinations. To gain knowledge
and understanding about possible interactions of redox partners and subsequent
transport of electrons to cytochromes P450 (P450s) molecular modelling methods
are vital. Increasing computational power makes in silico methods like molecular
docking and molecular dynamics simulations more and more suitable to analyze bio-
logical systems like P450s. With these methods we were able to establish changes in
progesterone hydroxylation and subsequently shift and increase the product spec-
trum. The introduction of modelled glycine and proline linker structures could
help to explain the interactions of proteins and the accompanied electron transfer.
Also we investigated combinations of redox partners to optimize the redox chain of
CYP106A2. To lower the redox potential of adrenodoxin, a suitable redox partner
of CYP106A2, methods of rational protein design were applied.

Zusammenfassung
Cytochrom P450 Enzyme sind breit einsetzbare Biokatalysatoren, die eine Vielzahl
an Substraten akzeptieren ko¨nnen, eine Fa¨higkeit die sie sehr attraktiv fu¨r eine
biotechnologische Anwendung macht. Trotz ihrer vielseitigen Einsetzbarkeit gibt
es jedoch einige Limitierungen, die es zu u¨berwinden gilt. Hierzu za¨hlen beispiel-
sweise die komplexen Elektronentransferprozesse oder die niedrige Elektronentrans-
ferrate. Die zur Elektronenu¨bertragung beno¨tigten Transferpartner sind u¨ber
verschiedene Organismen hinweg austauschbar und kombinierbar. Mit stetiger
Erho¨hung der Rechenleistungen werden in silico Methoden wie molekulares Docking
oder Moleku¨ldynamiksimulationen zur Analyse biologischer Systeme immer leichter
einsetzbar. Im Rahmen unserer Forschungsarbeiten konnten wir damit A¨nderungen
der Progesteronhydroxylierung bewirken, die das Produktspektrum verschob und
den Ertrag wesentlich erho¨hte. Die Modellierung von Glycin- und Prolin-Linker-
Strukturen trug dazu bei, Interaktionen der Redoxpartner und den einhergehen-
den Elektronentransfer zu erkla¨ren. Des Weiteren wurden verschiedene Kom-
binationsmo¨glichkeiten von Redoxpartnern zur Optimierung der Redoxkette von
CYP106A2 untersucht. Um das Redoxpotential von Adrenodoxin, einem passenden
Redoxpartner des CYP106A2, herabzusetzen, kamen Methoden des rationalen Pro-
teindesigns zum Einsatz.
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Chapter 1
Introduction
1.1 CYP P450 Enzymes
The discovery of cytochrome P450 enzymes (P450s or CYPs) as such lays back
around 60 years. In 1958, shortly after the discovery of Mason [1] and Hayashi [2],
Klingenberg [3] and Garfinkel [4] described a carbon monoxide (CO-) binding pig-
ment in rats and pigs liver microsomes. Only six years later its hemoproteioic nature
was proven by Omura and Sato [5] and the term Cytochrome P450 first showed up
in the scientific literature. The term P450 originates from the word pigment and the
characteristic absorption maximum of 450 nm shown by the reduced CO-complex.
During the 1960s a lot of fundamental discoveries were made, e.g. 1963 Estabrook
and coworkers discovered the oxygenase function in steroid metabolism [6], in 1965
Cooper learnt about the oxidation of diverse drugs in liver microsomes and Appleby
came up with the first P450 spectrum in bacterial cells in 1967. In the subsequent
year a major breakthrough was achieved by Gunsalus by the discovery of the bac-
terial P450 monooxygenase P450-CAM from Pseudomonas putida [7]. In contrast
to their mammalian counterparts, bacterial P450 enzymes are soluble, not attached
to a membrane and easy to purify. This allows for a subsequent production in large
quantities. From these findings many mechanistic and spectroscopic measurements
were seized up to the creation of the first crystallographic structure of P450-CAM
in 1985 (CYP101A1 ).
Due to technological improvement of genetic techniques in the 1980s more and more
P450 genes were described. To keep track a unique naming convention had to be
established. In 1987 Nebert and Gonzales [8] launched a standardised P450 nomen-
clature system based on sequence comparison. Here the term CYP is followed by an
arabic number representative for the CYP family with a minimum sequence identity
of 40%. The subfamily with a sequence identity of at least 55% is marked by a letter
and the individual gene again by a number. In 1995 David Nelson published a web-
page containing information of about 35,166 [9](as of April 2016) individual genes
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based on that nomenclature. The database is hand curated and contains information
from all kingdoms of life, such as animals, plants, fungi, protozoa, bacteria, archaea
and also viruses. Figure 1.1 shows the diverse gene distribution with the highest
number seen in plants with nearly 14000. Despite having sequence identities as low
Overview on total sequences throughout all kingdoms of life
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0 3500 7000 10500 14000
Figure 1.1: Distribution of P450 genes throughout all kingdoms of life (taken from [9]).
as 16% they still share the same structural fold since the very beginning. The only
conserved amino acid in all P450s is a cysteine that serves as a fifth ligand to the
heme iron [10].
1.1.1 Function
P450 enzymes are members of the heme b containing superfamily of monooxyge-
nases. Their ability to transform a broad variety of substrates such as fatty acids,
steroids, prostaglandines, pharmaceutical drugs, anaesthetics, ethanol, pesticides or
carcinogens as well as their involvement in hydroxylation, N-, O- and S-dealkylation,
sulphoxidation, epoxidation, deamination, desulphuration or peroxidation makes
them a pretty promising target for biotechnological applications.
Despite its manifold area of application, in reality, biotechnological usability is lim-
ited due to e.g. low activity of the enzyme, lacking amount of substrate bound
crystal structures for precise protein design, the need for electron transfer partners
and the limitations in electron transport. An excellent snapshot in time on chances
and limitations concerning biotechnological application of CYPs is provided in the
review of Bernhardt and Urlacher [11]. When using whole cell systems one is con-
fronted with problems such as NAD(P)H depletion, substrate solubility, as well as
substrate or product toxicity. During the actual catalytic cycle P450s transfer a
single atom of molecular oxygen to their substrate while reducing the other atom to
water (eq. 1.1).
RH +O2 +NAD(P )H +H
+ −→ ROH +H2O +NAD(P )+ (1.1)
For this reaction they are in need of external electron donors. Depending on the kind
of electron transfer from NAD(P)H, P450s are divided into four classes [10]. Whereas
class I and II enzymes receive electrons from a ferredoxin and a FAD containing
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reductant or just a FMN/FAD containing NADPH-P450 reductase respectively, class
III enzymes are self sufficient and do not need a donor. Class IV P450s get their
required electrons directly from NAD(P)H. Figure 1.2 shows a simplified scheme of
the hydroxylation process in P450s. In the first step ferric state iron gets reduced
upon electron acceptance into the ferrous state. After the subsequent binding of
dioxygen the second electron is introduced which leads to the cleavage of the O-O
bond. One of the oxygen atoms gets reduced to water whereas the other forms a
highly reactive ferryl intermediate (Fe=O). This intermediate adopts the hydrogen
from the RH molecule. The resulting free unstable R · radical accepts the OH group
while the ferryl iron transforms back to the ferric state.
Fe3+
Fe2+
O2
H2O
O2-
O3+
2 H+
RH
Fe Fe3+
Substrate RH
RH
e-
Fe2+
RH O
O
RH O
Fe3+
e-
RH
ROH
redox 
partner 
protein, e.g. 
adrenodoxin
redox 
partner 
protein, e.g. 
adrenodoxin
Figure 1.2: Simplified scheme of the catalytic cycle, common in almost every P450
enzyme
1.1.2 Electron Transfer
Electron transport to P450s is mediated through a complex multiprotein system.
An excellent overview of the various classes of electron transport chains was pub-
lished by Hannemann et al. in 2007 [12]. In general, electron transport systems
can be divided in two main classes (figure 1.3). Class I contains membrane-bound
adrenal mitochondrial P450s. Electron transfer from NAD(P)H includes a flavin-
containing reductase (ferredoxin/adrenodoxin reductase) and an iron-sulfur protein
(ferredoxin/adrenodoxin) [13]. On the other hand, in class II systems electron trans-
fer is realized with just one redox partner, a Flavin-Adenin-Dinucleotide (FAD) and
Flavin mononucleotide (FMN) containing reductase. In humans, 50 out of 57 P450s
are microsomal and are located in the endoplasmatic reticulum (ER). The remaining
ones are mitochondrial [13]. Most bacterial P450s belong to class I. They also use
two redox partners but are unlike their eukaryotic counterparts soluble and not at-
tached to the membrane. In the 1980s a first fused system was found [14, 15], which
was followed by other transport chains leading to a total of 10 different classes.
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The part as mediator of electron transport to P450s is taken over in many cases
by ferredoxins. Ferredoxins are small (6-25 kDa) acidic proteins that are nega-
tively charged at neutral pH. Their key feature is a iron-sulfur cluster as prosthetic
group. Depending on the number of iron-sulfur clusters they can be divided into
different classes ([2Fe-2S],[3Fe-3S] or [4Fe-4S] and combinations of them). [2Fe-2S]
ferrdoxins are subdivided into three classes namely plant-type, thioredoxin-type and
vertebrate-type (figure 1.4) [16].
P450
Fdx
FdR
NAD(P)H + H+
NAD(P)+
RH + O2
ROH + H2O
P450
Fdx
FdR
NAD(P)H + H+
NAD(P)+
RH + O2
ROH + H2O
Class 1 - Bacterial System
Class 1 - Mitochondrial System
Inner mitochondrial 
membrane
Figure 1.3: Overview of the different class 1 electron transport mechanisms
1.1.3 CYP106A2
CYP106A2 is a bacterial P450 from Bacillus megaterium ATCC 13368 with a molec-
ular mass of 47.5 kDa and a length of 410 amino acids. Despite the lack of knowledge
of its native function, it has the ability to hydroxylate not only steroids, but also
terpenoids or terpenes. In 1958 McAleer et. al [17] performed a 15β-hydroxylation
of progesterone through Bacillus megaterium. However, this was only proved more
than 20 years later [18]. Further investigation of Berg and coworkers identified the
hydroxylation-complex consisting of a P450, a NADPH-dependent megaredoxin re-
ductase and megaredoxin, an iron-sulfur cluster protein [18] - [23]. The recently
identified CYP106A2 from Bacillus megaterium has a sequence identity of 63% to
CYP106A1.
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Neither its redox partners are cloned yet, nor is its native substrate known. How-
ever, it can interact with the adrenal redox system such as adrenodoxin (Adx)
and adrenodoxin reductase (AdR) [20, 24] or with other electron transfer systems
of Bacillus subtilis [25] or Pseudomonas putida (Putidaredoxin and Putidaredoxin
reductase) [26]. Previous studies concentrated on the conversion and testing of
3 − oxo − ∆4-steroids mostly in the 15β position. Recently the first report of a
diterpene hydroxylation was published [27] as well as findings about conversions of
pentacyclic triterpene 11 − keto − β boswellic acid (KBA) [28] or the triterpenoid
dipterocarpol [29]. In 2016 Janocha et al. [30] published the first crystal structure
of CYP106A2 with and without a bound substrate (abietic acid) which was used in
part of my studies presented in the results chapters of this thesis.
Since CYP106A2 is a well established hydroxylase it could be an excellent candidate
for biotechnological, pharmaceutical or industrial application.
1.2 Adrenodoxin, Etp1fd and other ferredoxins
The name adrenodoxin (Adx) was derived from the tissue it was first isolated
from, the adrenal glands. Those are the manufacturing facilities of glucocorticoid-
, mineralcorticoid- and androgen-type steroid hormones [31][32][33]. As shown in
figure 1.4 it is a vertebrate-P450-type ferredoxin.
[2Fe-2S] Ferredoxins
P450-type Isc-type
Thioredoxin-typeVertebrate-typePlant-type
Example: Adx Example: Etp1fd
Figure 1.4: Overview of the different classes of [2Fe-2S] ferredoxins and the typical
allocation of Adx and Etp1fd.
Adx transfers electrons from NAD(P)H-dependent adrenodoxin reductases (AdR)
to CYP11 family CYPs in adrenal mitochondria as well as to microsomal CYPs
of families CYP17, CYP19 and CYP21 upon reconstruction. CYP11A1 is capable
of cleaving the side chain from cholesterol in three consecutive hydroxylation steps
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resulting in the precursor steroid hormone of all mammals: Pregnenolone. Addition-
ally Adx mediates electrons to CYP11B1 and CYP11B2 for subsequent production of
cortisol (glucocorticoid) and aldosterone (mineralglucocorticoid) [34][35][36]. Func-
tionally, Adx is a [2Fe2S] type ferredoxin, whereby the side chains of four cysteines
as well as the two bridging sulfur atoms form an approximately tetrahedral coordi-
nation around each of the two iron atoms of the iron-sulfur cluster. This is known
from several X-ray crystallographic structures of oxidized bovine Adx (pdb entry
codes 1AYF, 1CJE). Of interest are also the one of the isolated human Adx (3P1M)
and that of the complex with CYP11A1 (3N9Y), showing the binding interface [37].
Comparison of the structural changes upon reduction of bovine Adx determined by
NMR spectroscopy suggests that the largest deviations occur in the region 68-85,
which comprises the primary interaction region to the cytochrome [38]. In experi-
mental and theoretical studies mostly human and bovine Adx are used. Both their
mRNAs encode for a N-terminal extension of the mature protein. In bovine Adx the
extension is about 58 amino acids long and serves as a mitochondrial targeting se-
quence, which is cleaved upon mitochondrial entry. The resulting mature ferredoxin
weighs about 14.4 kDa and has a length of 128 amino acids. An Adx-like ferredoxin
from Schizosaccharomyces pombe can be found as being part of the electron trans-
port protein 1 (Etp1) [39]. Etp1 is composed of an approximately 400 amino acid
long N-terminal (homologous to COX15 in humans) and a C-terminal ferredoxin
domain (homologous to Adx) part named Etp1fd. Its native task includes the sup-
port of assembling iron-sulfur clusters as well as the synthesis of heme A [40]. In
2002 the ability of electron transport in steroid hydroxylation processes in bacterial
and mammal P450s was discovered [39]. In certain reactions Adx can be replaced
by Etp1fd. In addition to that there are other P450s and lsc-associated ferredoxins
that share a surprisingly high sequence identity (even having different physiological
functions, e.g. Adx is quite similar to Etp1fd (sequence similarity of 39% [40]) or
to Pdx (sequence similarity of 40% [41])). Also they share some highly conserved
regions which is shown in figure 1.5.Three of them are placed around the iron-sulfur
clusters of the proteins.
To quantify for the efficiency of electron transfer from a ferredoxin to a P450 the
midpoint redox potential indicated in mV can be used. From the thermodynamic
point of view it is obvious that the lower the value, the faster the electron transfer
and the faster the reaction should be. An overview over the previous mentioned
ferredoxins is given in table 1.1.
1.3 Steroid Hormones
Steroids are small molecules that have regulatory functions and belong to the group
of lipids. They all have a characteristic base structure consisting of 17 carbon atoms
arranged in three cyclohexane rings and one cyclopentane ring (fig. 1.6). Molecules
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Figure 1.5: Sequence alignment of different ferredoxins. There are three conserved
regions marked in the picture (bold and pale colors indicate highly and lower conserved
regions, respectively, within the sequence; colors are just for clarification).
Ferredoxine (Organism) Redox potential[mV] PDB id
Adx WT (Bos taurus) [42] -274 1AYF chain B
4-128 (Bos taurus) [43] -267
4-114 (Bos taurus) [44] -342
4-108 (Bos taurus) [45] -344
Etp1 (S. pombe) [46] -353 2WLB chain B
FdX (E.coli) [47] -380 1I7H chain A
FdxE / FdVI (R. capsulatus) [48] -306 1UWM chain A
PdX (P. putida) [49] -240 1XLQ chain A
Table 1.1: Overview of different P450 type and lsc-type Ferredoxins with corresponding
redox potentials
like sterols, bile acids, steroid hormones, vitamin D and also many other secondary
metabolites again belong to the group of steroids. They were found and identified
in animals, plants and as well as in lower eukaryotes such as yeast or fungi [50, 51].
In humans the steroid hormones are synthesized in the adrenal glands or gonads.
They steer the water/electrolyte homeostasis (aldosterone), the energy mobilization
and immune response (cortisol) or account for sexual characteristics (testosterone,
estrone). Even in gestational reactions (progesterone), cell communication processes
and cell proliferation they play a major role [52]. The central steroid hormone is
cholesterol. It is the common precursor to all mammalian steroid hormones and all
others evolve from it. A rough scheme of the complexity involved in steroid hormone
synthesis originating from cholesterol is shown in figure 1.7. As mentioned they play
a central role as regulatory substances. Hence they are very interesting for pharma-
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Figure 1.6: Basic structure of steroids. Consisting of 17 carbon atoms arranged in three
cyclohexane rings and one cyclopentane ring
ceutical application. Representing one of the largest sectors of the pharmaceutical
industry (besides antibiotics), they list more than 300 approved drugs [53, 54]. In
addition to it the alternatively hydroxylated compounds have advantages towards
their natural counterparts such as lowering occurring side effects, higher potency or
other activating or inhibiting properties [55]. A big challenge in future research is to
create new efficient ways to synthesize steroid hormones by biotechnological means.
1.4 Aim and Scope of This Work
The global aim of this work was the increase of selectivity and activity of P450
enzymes and the optimal adaption of redox partner interactions. The first part
includes engineering of well known CYPs like CYP106A2 towards an efficient and
selective mode to increase the selectivity of certain substrate conversions. Here we
focused mostly on progesterone and its diverse hydroxylation possibilities. To guar-
antee an efficient way of electron transfer its redox partners must fit together nicely.
Therefore engineering on the surface and the inner structure was performed in order
to increase the fitting of the surfaces. Our suggestions were tested and partially
verified in the wet lab.
The thesis first gives an introduction on the biological background. Here an up to
date overview on CYP P450s, electron transfer proteins as well as common ligands
is provided.
The following chapter deals with the methodology that was used to theoretically in-
vestigate and tackle occurring problems for optimizing protein-protein interactions
or protein-ligand interactions in P450 specific environments at the computational
level. It provides the theoretical background that needs to be understood to apply
the right methods for the given cases.
In chapters three to six I show the results of published and soon to be published work
in joint cooperations with our coworkers. Chapter three summarizes the investiga-
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Figure 1.7: Simplified scheme of steroid hormones synthesis pathways originating from
cholesterol.
tion of different combinations of ferredoxins and ferredoxin reductases towards an
optimal redox system for progesterone synthesis through CYP106A2. Here we were
also able to show why Etp1 binds more optimal to CYP106A2 than Adx and sug-
gested a mutation to improve Adx’ binding to CYP106A2. The results summarized
in chapter four and published in Steroids [55] suggested theoretically derived muta-
tions in the amino acid sequence of CYP106A2 for shifting 15β-hydroxy-progesterone
production towards 6β-, 9α- and 11α-hydroxy-progesterone. Subsequent Molecular
Dynamics simulations were carried out to show the behaviour of progesterone in the
binding pocket over time. Closing the section on improvement of Adx’ redox poten-
tial through mutations is done in chapter five. Here an approach from 1997 of Zhou
[56] was revisited. They state that the change of the direction of the dipole moment
can increase or decrease the redox potential on iron-sulfur cluster proteins, respec-
tively. A theoretical investigation was performed with suggestions for mutations on
Adx. An experimental verification still needs to be carried out. Chapter six deals
with redox complexes of electron transfer proteins that were fused with different
linker constructs. Here we were able to explain why certain linkers improved the
performance of the fused proteins whereas others did not.
A conclusion at the end summarizes my efforts and provides also insights into failed
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attempts to generate an universal system for predicting mutations to improve the
redox potential for Adx. Subsequently I give an outlook about possible future work
in this field.
Chapter 2
Materials and Methods
In this chapter I will describe the different computational methods that were used
during my thesis. It introduces the concept of molecular dynamics (MD) simulations
and guides through the basic physics lying underneath ending up in the full algorithm
that performs such a simulation. This is followed by the introduction to Docking
and density functional theory. The chapter is rounded up by an overview over the
Adaptive Poisson-Boltzmann Solver developed by Nathan Baker and co workers [57].
2.1 Molecular Dynamics Simulations
MD simulation is a molecular modeling technique to describe the dynamics, con-
formational changes or thermodynamics in a molecular system. They end up in a
trajectory that documents how the positions and velocities of particles change inside
a defined time frame. The systems configurations are generated by the numerical
solution to Newton’s second law :
F = ma (2.1)
where the force F is a result of mass of the particle times its acceleration. Since
the acceleration is the first derivative of the velocity v and the second derivative of
position r with respect to time t one can rewrite equation 2.1 explicitly for each
particle as:
Fri = mi
d2ri
dt2
(2.2)
Due to the size of the systems and the coupling between the particles equation 2.2
cannot be solved analytically. The integration of the equation can be solved with a
numerical solution such as finite differences method. Here the dynamic properties
like acceleration, velocities etc. and positions are approximated with a Taylor series
expansion.
In molecular dynamics simulations the most common method for solving Newton’s
11
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equation of motion is the Verlet algorithm [58]. The Verlet algorithm computes the
positions of the particles for the next time step from the position of the particle
from the previous time step t−∆t:
r(t−∆t) = r(t)−∆tv(t) + 1
2
∆t2a(t)− . . . (2.3)
and the acceleration and position of the particle from the actual time step t:
r(t+ ∆t) = r(t) + ∆tv(t) +
1
2
∆t2a(t) + . . . (2.4)
combined the two equations result in:
r(t+ ∆t) = 2r(t)− r(t−∆t) + ∆t2a(t) (2.5)
A drawback as it is in this basic form of the algorithm is the lack of explicit naming
of the velocity of the particles. The velocities are important when it comes to
calculation of the kinetic energy of the system and thus the temperature. A variation
of the Verlet algorithm that overcomes this difficulty is the leap-frog algorithm [59].
It calculates the position of the next time step from the particles actual position
and the velocity from a time step t+ 1
2
δt:
r(t+ ∆t) = r(t) + ∆tv(t+
1
2
∆t) (2.6)
Before that the velocity at that time step are first updated:
v(t+
1
2
∆t) = v(t− 1
2
∆t) + ∆ta(t) (2.7)
Setup of a MD simulation requires an initial configuration of the system. A starting
geometry can be derived from a theoretical model, an experiment (crystal structure)
or combination of both. The assignments for the velocities is usually done by ran-
domly picking values from a Maxwell-Boltzmann distribution, which is essentially a
Gaussian distribution:
p(vix) = (
mi
2pikbT
)
1
2 × exp[−1
2
miv
2
ix
kbT
] (2.8)
Equation 2.8 gives the probability that atom i with mass mi has a velocity of vix
in x direction at temperature T.
Generally before a MD simulation itself, some preparatory steps need to be carried
out. A typical MD simulation comprises of the following parts:
1. Define and prepare starting geometry
2. Energy Minimization
3. Equilibration
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4. Production MD
5. Analysis
Depending on the kind of experiment first one needs to define and curate (check for
missing atoms etc.) the starting geometry (e.g. crystal structure from Protein Data
Bank (www.rcsb.org [60])). In subsequent steps the experiment gets discretized
and specified in detail. First the appropriate force field has to be chosen which
has to fit the users needs. GROMACS [61] for example lets the user choose from
a range of different force fields (e.g. AMBER[62], CHARMM[63], GROMOS[64] or
OPLSAA[65]). After that a spatial specification is needed where the user decides for
a shape where and in what medium the molecule is simulated in (solvents, vacuum).
To obtain a net neutral charge of the system, positively or negatively charged ions
can be added. From that on the energy minimization step can be started where steric
clashes or inappropriate geometries are resolved (they emerge for example from the
principal limitations of crystallographic coordinates of atoms). The molecule is now
mostly optimized within itself but not with respect to its surrounding. Necessary
Equilibration is performed in two phases. The first phase comprises the temperature
setting whereas the second comprises the pressure settings of the whole system.
Under a NVT (Number of particles; Volume; Temperature) ensemble the system
is stepwise heated up to the temperature the simulation should be performed at.
This is usually realized via a certain thermostat (e.g. [66]). To reflect that also
the (atmospheric) pressure does not vary, an analog equilibration proceeds. Here
the preferred pressure is conducted under a NPT (Number of particles; Pressure;
Temperature) ensemble via a certain barostat (e.g. [67]).
The now equilibrated system can be used to run a production MD simulation for a
defined time frame.
The time needed depends on the size of the molecule(s). E.g. a equilibrating time of
50-100 ps for NVT and NPT suffices a 130 amino acid long protein. The subsequent
MD simulation should last at least 20 ns. A standard time step size is 2 fs (for
this case the simulation comprises of 10,000,000 computation steps). Since such a
computation would last weeks to months, MD simulations are usually performed
on computer clusters or supercomputers that are highly parallelizable. Subsequent
Molecular motion Time [s]
Atomic fluctuations/Side-chain motion 10−15 - 10−12
Loop & Rigid-body Motion 10−9 - 10−6
Domain and Subunit Motion 10−6 - 10−3
Protein (Un-) Folding 10−3 - 104
Table 2.1: Scheme of captured motion of molecules for different time spans
to simulation the computed trajectories (snapshots of the simulation at fixed time
frames) are analyzed. Here for example the RMSD value over time or the spatial
behaviour of the molecule(s) is(are) of interest.
14 CHAPTER 2. MATERIALS AND METHODS
2.2 Docking
Computer aided molecule design has not only become a crucial part in development
of new drugs but also is a helpful method for biotechnological purposes. An impor-
tant tool in this area is molecular docking [68]. Docking allows for investigation of
molecular interactions in terms of geometry as well as electrostatics and estimates
the binding affinity and the mutual orientation between a receptor and ligand by
means of the underlying scoring function. The conformational space that has to be
sampled is huge, even if both protein and ligand are treated as rigid bodies. Not
only the three degrees of freedom from ligand relative to the protein have to be con-
sidered but also the additional internal degrees of the ligand itself that arise from
rotatable bonds. Additionally, induced-fit phenomena are neglected, when consid-
ering the protein as rigid body. The subsequent evaluation by a scoring function
[69] of each protein-ligand conformation should eventually come up with a pose that
could occur in nature. But there are different ways how one can evaluate a score for
a pose. Some scoring functions are based on the underlying force field, on knowledge
or are even empirical and usually include a weighting for individual terms that were
fitted and trained on known sets of protein-ligand complexes. Therefore not every
evaluation will work as desired on each kind of receptor ligand complex [68] [70].
Since the early days of docking with rigid protein and ligand (e.g. DOCK [71]),
algorithms more and more incorporated full flexibility for ligands and partially re-
ceptors. In the following paragraph concepts behind automated docking will be
explained by means of the widely used AutoGrid4 and AutoDock4 [72] software.
The visual molecule inspecting program AutoDockTools can produce input files for
both command line tools AutoGrid4 and AutoDock4. Hereby the the actual search
pace will be exactly defined. In the beginning a grid placed into the receptor where
on each grid point the electrostatic potential between every atom type occurring
in the ligand and the receptor is calculated (grid density can be varied). After the
precomputation step the actual docking step can be performed. The optimization of
the receptor-ligand pose and their corresponding interaction energy is performed by
a Lamarckian Genetic Algorithm (LGA) [73]. Generally a GA implements Darwins
law of evolution by natural selection. A conformation is assessed with a fitness score
via the scoring function and the best ones pass on their genes (conformation) to
the next generation. The conformation then will be recombined, randomly mutated
or left unchanged. The score estimates the binding free energy ∆G of the complex
in a solvated state with a semi-empirical free energy force field. The force field in
particular is already trained and parameterized using a large number of protein-
inhibitor complexes. It uses six pair-wise evaluations (V) and an estimation of the
conformational entropy lost due to binding (∆Sconf ):
∆G = (V L−Lbound − V L−Lunbound) + (V P−Pbound − V P−Punbound) + (V P−Lbound − V P−Lunbound + ∆Sconf ) (2.9)
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For each term in 2.9 energetic terms have to be computed including evaluations for
repulsion/dispersion, hydrogen bonding, electrostatics and desolvation, respectively.
∆G = ∆GvdW
∑
i,j
(
Aij
r12ij
− Bij
r6ij
)
+ ∆Ghbond
∑
i,j
E(t)(
Cij
r12ij
− Dij
r10ij
)
+ ∆Gelec
∑
i,j
qiqj
e(rij)rij
+ ∆Gsol
∑
i,j
(SiVj + SjVi)e
−r2ij/2σ2
+ ∆GtorNtor
(2.10)
The first term describes the repulsion/dispersion value (van der Waals interaction)
between all atom pairs i and j using a Lennard-Jones potential. To account for
hydrogen bonding a 12-10 potential is used with the integration of E(t), defining the
direction of the bond with angle t. The third term denotes the Coulomb interactions
and the fourth term the desolvation potential. Hereby Si gives the required energy
that is needed to transfer atom i from a solvated state to a buried one. Vi estimates
the amount of desolvation due to ligand complexation. Upon bonding, there is a
loss of entropy that is proportional to the number of sp3 bonds, Ntor. The weighting
constants ∆G were derived from a set of experimentally known binding constants.
2.3 Density Functional Theory
To almost all physical properties of a system, the electronic ground state is fun-
damentally important. The Density Functional Theory (DFT) approaches a solu-
tion to the partial differential equation that describes the behaviour of atoms and
molecules over time, namely the Schro¨dinger equation. In its most general form, the
time-dependent form reads as:
ih¯
δ
δt
Ψ(r, t) = HˆΨ(r, t) (2.11)
where i denotes the imaginary unit, h¯ the reduced Planck constant, δ
δt
the partial
derivative with respect to time of the wave function Ψ of the system with r and
t being the spatial vector and time. Hˆ is the Hamiltonian operator. Through
minimization of the total energy of the system the ground state wave function can
be found. The wave function Ψ is a many-body function that contains coordinates
for all degrees of freedom of a system. Analytical solutions to the Schro¨dinger
equation cannot exceed the two-body form such as one hydrogen atom with one
nucleus and one electron. The complexity increases by three times the degrees of
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freedom. For example for an oxygen atom with its electrons this would mean to
solve a 24-dimensional partial differential equation [74].
Classical mechanics are not capable of describing or solving this problem. To be able
to do that one has to specify the location of an atom, hence the location of the nucleus
(protons and neutrons) and the electrons. Since protons and neutrons are much
heavier then the electrons (approx. 1800 times [75]), the electrons respond much
more rapidly to changes in their surroundings. Applying the Born-Oppenheimer
approximation [76] the computation of the wave function can be done by separating
the wave function into its electronic and nucleic components.
Ψtot = Ψelec ×Ψnuc (2.12)
Following the Born-Oppenheimer approximation and neglecting the nuclei one could
write the Hamiltonian for the electrons from equation 2.11 as:
ih¯
δ
δt
Ψ(r, t) = [
h¯2
2me
∑
i
∇2i +
∑
i
Vext(ri) +
1
2
∑
i 6=j
e2
|ri − rj| ]Ψ(r, t) (2.13)
where the Hˆ is replaced by terms for the kinetic energy of each electron, the inter-
action energy between the electrons and the collection of nuclei and the interaction
energy between different electrons. In 1964 Hohenberg and Kohn [77] stated that
the external potential E is a unique functional of the electron density ρ(r). A func-
tional allows a function to be mapped to a number. This leads to a simplification
that reduces the number of variables to handle from 3N (N as number of electrons)
to 3 (electron density). In DFT the energy functional is defined as follows:
E[ρ(r)] =
∫
Vext(r)ρ(r)dr + F [ρ(r)] (2.14)
Vext(r) accounts for the interaction of electrons with an external potential and
F [ρ(r)] denotes the sum of the kinetic energy. Essentially the minimum energy
complies with the ground state electron density. Since the wave function F [ρ(r)] is
not known, Kohn and Sham 1965 [78] came up with the approximation:
F [ρ(r)] = EKE[ρ(r)] + EH [ρ(r)] + EχC [ρ(r)] (2.15)
Here the wave function is equal to the sum of the kinetic energy (from non-interacting
electrons with the same density as the real system) which writes as:
EKE[ρ(r)] =
N∑
i=1
∫
Ψi(r)(−∇
2
2
)Ψ(r)dr (2.16)
Electron-electron Coulombic energy which is also known as Hartree electrostatic
energy is described by the second term of equation 2.15. The Hartree approach fails
to incorporate the correlation of electron movement and therefore is only a part
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of equation 2.15. The Hartree energy term integrates the interaction between two
charge densities and can be rewritten as:
EH [ρ(r)] =
1
2
∫ ∫
ρ(r1)ρ(r2)
|r1r2| dr1dr2 (2.17)
The last term in equation 2.15 denotes contributions from exchange and correlation
that are typically computed from a set of functions, namely basis functions that are
linearly combined to create molecular orbitals. In practise, the amount of correlation
and exchange can be optimized to the problem at hand and therefore a multitude
of DFT functional has been developed.
If we now let equations 2.16 and 2.17 flow together we end up with the full Kohn
Sham equation to compute the energy of a N-electron system:
E[ρ(r)] =
N∑
i=1
∫
Ψi(r)(−∇
2
2
)Ψ(r)dr
+
1
2
∫ ∫
ρ(r1)ρ(r2)
|r1r2| dr1dr2
+ EχC [ρ(r)]
−
M∑
A=1
∫
ZA
|r −RA|ρ(r)dr
(2.18)
2.4 Adaptive Poisson-Boltzmann Solver
To calculate electrostatic interactions between proteins or proteins and ligands I
used the Adaptive Poisson Boltzmann Solver software developed by Nathan Baker
[57]. The basics for electrostatics consist on the Poisson equation and the Boltz-
mann distribution of ions in solution and continuum models.
To investigate the electrostatic properties of biological macromolecules (e.g. pro-
teins) the Poisson equation is widely used. Hereby the solute is treated as body of
constant dielectric (between 2 and 20) whereas the solvent is represented as contin-
uum of high dielectric. The Poisson equation relates the variation in the potential
φ within dielectric constant  to the charge density ρ:
∇(r)∇φ(r) + 4piρ(r) = 0 (2.19)
Now the Boltzmann distribution describes a probability that a system is in a certain
state that is defined by a function of that states temperature, energy and number
of atoms. The distribution is defined as:
n(r) = Ne−
qφ(r)
kT (2.20)
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t = m + 1
t = m
Figure 2.1: Stencil for discretization in two-dimensional case. Value of timestep t is
dependent on time step t−∆t
Merging equations 2.19 and 2.20 result in the well-known Poisson-Boltzmann equa-
tion (PBE), the most frequently used continuum modeling equation for protein-
solvent systems:
∇[(r)∇φ(r)]− κ′2φ(r) + 4piρ(r)
kT
= 0 (2.21)
As any other linear or nonlinear partial differential equation the PBE is hard to solve
analytically. This is only feasible to simple geometries such as spheres, cylinders or
plains. Numerical solutions such as finite differences, elements or volumes methods
for approximation are widely used. The steps for solving the PBE involve:
1. Discretization of the spatial domain
2. Assignment of values for electrostatic potential, charge density, dielectric con-
stant and ionic strength to each discrete grid point
3. Determination of derivatives for PBE by numerical methods
An example for a discretization method would be the finite differences method. Here
the actual potential of a grid point is dependent on the surrounding grid points as
well as the previous time step. In a two-dimensional space (for simplification) that
would be four neighbouring grid points as shown in figure 2.1. The potential at each
grid point would be:
φ0 =
∑
iφi + 4pi
q0
h∑
i + κ
′2
0 f(φ0)
(2.22)
The total energy of a system is computed from two necessary simulations, namely
the system in vacuum and in solution. The solvation energy is computed from point
charges located on the particles and different potentials:
∆Gelec =
1
2
∑
1
qi(φ
80
i − φ1i ) (2.23)
A very simple to use tool to compute electrostatic properties for biomolecules is
the Adaptive Poisson Boltzmann Solver (APBS). It can be used via web server or
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locally. Configuration of input files, like assignment of charges, can be done by a
co-program named pdb2pqr [79] [80]. This generates charge files ready to use for
APBS. APBS solves the PBE with a finite elements approach.
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Chapter 3
Towards an optimal redox chain
for CYP106A2 from Bacillus
megaterium ATCC 13368
The results and discussion sections (3.1 and 3.2) as well as figures 3.1, 3.2, 3.3, 3.4,
3.5, 3.6, 3.7, 3.8, 3.9, 3.10 and table 3.1 were adapted unaltered from our submitted
manuscript [81], whereas the experimental section of our coworkers is omitted here.
The work presented in this chapter emerged from a collaboration together with the
group of Prof. Dr. Rita Bernhardt and is in revision process. It aims towards
an optimal redox chain for CYP106A2 from Bacillus megaterium ATCC13368 for
progesterone conversion.
Progesterone was chosen as substrate since it is well studied as a substrate for
CYP106A2. Besides the main product 15β-hydroxy-progesterone other monohy-
droxylated products like 6β-, 9α- or 11α-hydroxyprogesterone can emerge in low
quantities [82, 83]. Additionally polyhydroxylated progesterone products were also
found.
The most preferred redox system used for substrate conversion with CYP106A2 is
bovine Adrenodoxin (Adx) and its reductase Adrenodoxin reductase (AdR). How-
ever, in order to achieve an optimal redox system with a higher yield of substrate
conversion, 11 different combinations of the following ferredoxins or flavodoxins were
tested:
1. Ferredoxins/Flavodoxins:
(a) Adx (Bos taurus)
(b) Adx(4-108) (Bos taurus)
(c) Etp1(516-618) (Schizosaccharomyces pombe)
(d) Fdx2 (Bacillus megaterium)
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(e) FldA (Escherichia coli)
(f) YkuN (Bacillus subtilis)
2. Reductases
(a) AdR (Bos taurus)
(b) Arh1 (Schizosaccharomyces pombe)
(c) BmCPR (Bacillus megaterium)
(d) Fpr (Escherichia coli)
It was shown that the choice of redox partner not only affects the rate of substrate
conversion but also strongly influences the product pattern in terms of multi-product
conversion. The best fitting system yielded a high rate of 15-β-hydroxy-progesteron
and kept the conversion of unwanted multihydroxylated products low.
Manual investigation of the crystal structures of Etp1 and Adx and subsequent dock-
ing experiments lead to the identification of significant alterations in their similar
three dimensional conformation that probably account for faster electron transfer
rates of Etp1.
3.1 Results
To test the ability of the various redox chains for their efficiency to transfer electrons
from NAD(P)H to CYP106A2, in vitro experiments using various heterologous re-
dox systems were conducted. The typically used redox system for CYP106A2 is the
truncated form of bovine adrenodoxin, Adx(4-108), and the corresponding reduc-
tase, AdR, which was therefore used as “parent” system. We investigated different
naturally occuring redox protein systems as well as combinations between them.
The redox system of Schizosaccaromyces pombe, consisting of the ferredoxin Etp1
(electron transfer protein 1) and ferredoxin reductase Arh1 (adrenodoxin reductase
homolog 1), is completely soluble and easily expressable [84, 85]. With the bacte-
rial CYP105A1 from Streptomyces griseolus, the reduction efficiency was shown to
be 100% for the combination of Etp1/Arh1 compared with only ∼25% when us-
ing Adx(4-108)/AdR [86]. The lower redox potential of Etp1 of -353 mV instead
of -344 mV is likely to be a major driving force that would explain this. Other
possiblities to investigate are the full-length bovine adrenodoxin, which works bet-
ter with CYP11A1 [87], than the truncated form (Adx(4-108)) that is mostly used
for CYP106A2, as well as redox partners from different Bacillus strains, such as
the ferredoxin isolated from Bacillus megaterium DSM319, Fdx2 [88], the typi-
cal short-chain flavodoxin YkuN from Bacillus subtilis [89], the Bacillus mega-
terium cytochrome P450 reductase BmCPR [90], or redox partners from Escherichia
coli like the flavodoxin FldA and NADPH-dependent flavodoxin/ferredoxin reduc-
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tase Fpr [91, 92, 93] (fig. 3.1). First tests were conducted with a fixed ratio
	
Figure 3.1: Schematic drawing of the investigated redox partner proteins. Redox equiv-
alents are transferred from NADPH via a reductase (AdR, Arh1, Fpr, BmCPR) and a
ferredoxin (Adx, Adx(4-108), Etp1(516-618), Fdx2), or flavodoxin (FldA, YkuN)) to the
progesterone converting enzyme CYP106A2 (taken from [81])
of CYP:ferredoxin:reductase of 1:20:2 (exceptions for CYP:FldA:Fpr=1:50:50 and
CYP:YkuN:Fpr=1:10:10) for 30 min to check the compatibility of redox proteins
with CYP106A2 (fig. 3.2). The product patterns of the progesterone conversion
differentiate clearly between the tested combinations of redox partners. Some com-
binations have similar overall conversion rates but produce more than 60 % polyhy-
droxylated progesterones (Adx(4-108)/Arh1), whereas others tend to give more than
70 % 15β-OH-P (Etp1(516-618)/AdR). Also redox partner combinations which have
slower conversion rates are distinguisable (Adx/AdR). Using the above mentioned
conditions (ratio of enzymes, temperature, time, in vitro components), it is clearly
visible that the ferredoxin Adx(4-108) (combined with AdR) produces an abundance
of polyhydroxylated products, whereas the wildtype Adx as well as the FldA have
an overall lower conversion of progesterone (figs. 3.2 and 3.3). Etp1(516-618) is
showing a very high conversion (similar to Adx(4-108)/AdR) but a low amount of
polyhydroxylated progesterone products. The combination of Adx(4-108) and Bm-
CPR displays a high conversion also exhibiting low amounts of polyhydroxylated
products. Another way to get a deeper insight into the redox partner exchange is
to look at the absolute amounts of converted progesterone and its products, which
are displayed in figure 3.3. The combination of Etp1(516-618) and AdR was able
to convert the total of 199 µM progesterone in the 250 µl in vitro assay within 30
min. Almost all truncated ferredoxins were able to convert between 180 and 190
µM progesterone. When Adx(4-108) or Etp1(516-618) were reconstituted with Bm-
CPR, only 10 to 40 µM progesterone were not converted. Full-length Adx(1-128)
or Fdx2 were able to convert between 118 and 143 µM progesterone to its prod-
ucts, whereas FldA (in combination with the corresponding reductase, Fpr) only
converted 53 µM of the substrate. In contrast, when Fpr was combined with the
flavodoxin from Bacillus subtilis, YkuN, 183 µM of progesterone was converted. All
combinations (except FldA/Fpr) tested did not remarkably change the amount of
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Figure 3.2: Comparison of in vitro conversions of progesterone with CYP106A2 and
different redox partner combinations. Reactions were run for 30 minutes while keeping
the ration of CYP:ferredoxin:reductase at 1:20:2 (exept for CYP:FldA/Fpr=1:50:50 and
CYP:YkuN:Fpr=1:10:10); dotted bars indicate polyhydroxylated progesterone products,
grey bars indicate the main product 15β-OH-P, diagonally striped bars indicate other
monohydroxylated progesterone products (e.g. 11α-, 9α-, and 6β-hydroxyprogesterone),
horizontally striped bars indicate the remaining substrate progesterone. The relative par-
ticular product level was calculated by using the relative peak area of the specific product
compared to the total peak areas of educt and products (taken from [81]).
the other monohydroxlated progesterone products (6β-, 9α-, and 11α), which al-
ways was between 3 and 5 % under the conditions being tested. Switching the
established bovine reductase, AdR, to the yeast Arh1 resulted in only little changes:
27 % of the total product consists of the main product, 15β-OH-P, when using AdR
as reductase, and 31 % when using Arh1. Also, a difference in polyhydroxylated
progesterone is not notable, which is 65 % and 64 % when using AdR and Arh1,
respectively. In both cases the other monohydroxylated progesterone products (6β,
9α, 11α) were formed at a level of 5 %. When replacing the ferredoxin from Adx(4-
108) to Etp1(516-618), the change in the product distribution is remarkable. The
combination of Etp1(516-618) and AdR resulted in 78 % main product and only 18
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Figure 3.3: Comparison of the absolute amounts of detectable substrate and prod-
ucts after in vitro conversion of progesterone with CYP106A2 and different redox
partner combinations. Reactions were run for 30 minutes while keeping the ra-
tion of CYP:ferredoxin:reductase at 1:20:2 (exept for CYP:FldA/Fpr=1:50:50 and
CYP:YkuN:Fpr=1:10:10); dotted bars indicate polyhydroxylated progesterone products,
grey bars indicate the main product 15β-OH-P, diagonally striped bars indicate other
monohydroxylated progesterone products (e.g. 11α-, 9α-, and 6β-hydroxyprogesterone),
horizontally striped bars indicate the remaining substrate progesterone (taken from [81]).
% polyhydroxylated progesterone, which is a 2,6-fold increase in the main product
when compared with Adx(4-108)/AdR. Also the source of reductase seems to affect
the product pattern. The use of Arh1 resulted in 66 % main product and 26 %
poly-OH-progesterone compared with 78 % and 18 % when AdR was used (fig. 3.2).
Applying the full-length Adx(1-128), also completely changes the product formation:
there is still 41 % and 36 % substrate left (in combination with AdR and Arh1, re-
spectively), but there is also 53 % and 58 % of 15β-OH-P formed. The amount of
polyhydroxylated products is negligable. The use of Fdx2 from Bacillus megaterium
results in 66 % main product and 29 % of unconverted substrate. No polyhydrox-
ylated products were formed. In contrast, the redox partners originating from E.
coli, FldA and Fpr, were not able to provide electrons to CYP106A2 when a ratio of
CYP:ferredoxin:reductase of 1:20:2 was applied, which resulted in no product forma-
tion (data not shown). Therefore, the ratio was increased to 1:50:50, which lead to
a conversion of 27% (all main product). Exchanging the FldA with the YkuN from
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Bacillus subtilis (at a ratio of 1:10:10), a production of 24 % poly-OH-progesterone
and 63 % main product was observed. Surprisingly, the use of the very recently
cloned and characterized Bacillus megaterium reductase BmCPR [90] resulted in 80
% and 72 % 15β-OH-P and only 10 % and 4 % poly-OH-P formation, respectively.
These data demonstrate that the application of different redox systems can alter
not only the conversion rate of the substrate, but also the product distribution. To
gain deeper insight into the time dependence of the progesterone conversion and
product distribution by CYP106A2, the combinations of the ferredoxins Adx(4-108)
and Etp1(516-618) with AdR and Arh1 were investigated in more detail.
	
Figure 3.4: Time-dependent in vitro conversion of progesterone by CYP106A2 and
Adx(4-108)/AdR. Conversions were stopped after 1, 5, 10, 15, 30, 45, or 60 minutes; dot-
ted lines indicate polyhydroxylated progesterone products, grey lines indicate the main
product 15β-OH-P, dashed with single dot lines indicate other monohydroxylated proges-
terone products, dashed lines indicate the remaining substrate progesterone. Within 10
minutes, 93 % of progesterone has been converted and 65 % of 15β-OH-P was produced.
Further conversion leads to an increase in polyhydroxylated progesterone products and a
decrease of the main product, 15β-OH-P. The percentage of other monohydroxylated did
not change within the considered time interval (taken from [81]).
When using Adx(4-108)/AdR (fig. 3.4), the steep increase of 15β-OH-P formation
up to 67% (5 min) is followed by a decrease to 34% after 60 min. At the same time,
the amount of polyhydroxylated progesterone is slowly increasing from 7% after 5
min to 59% after 60 min. This suggests that the main product is partially further
hydroxylated to result in polyhydroxylated end products. After changing AdR for
Arh1 (see fig. 3.5), the time dependence of progesterone conversion was almost
identical. First, the main product increased to 76% (5 min), dropping to 27% after 60
min, while poly-OH-progesterone is increasing up to 66% (60 min). Using Etp1(516-
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Figure 3.5: Time-dependent in vitro conversion of progesterone by CYP106A2 and
Adx(4-108)/Arh1. Conversions were stopped after 1, 5, 10, 15, 30, 45, or 60 minutes;
dotted lines indicate polyhydroxylated progesterone products, grey lines indicate the main
product 15β-OH-P, dashed with single dot lines indicate other monohydroxylated proges-
terone products, dashed lines indicate the remaining substrate progesterone. The con-
version of progesteron is almost complete after 5 min (1 % left), whereas the rate of
15β-OH-P (76%) decreases fast after 5 min while increasing amounts of polyhydroxylated
progesterones are formed (up to 66 %). Also, further monohydroxylated products range
at about 4 % over the time course of 60 minutes (taken from [81]).
618) as a ferredoxin (fig. 3.6) with AdR as corresponding reductase, a steep increase
of 15β-OH-P formation to 75% within in the first 5 min is followed by a slow increase
up to 81% after 60 min. In this case, a slow rise of poly-OH-progesterone (not
reducing the amount of the main product) to 14% after 60 min occurs. Changing
the reductase for Arh1 (fig. 3.7), the highest main product formation is observed
after 10 min (78%), dropping slightly to 69% after 60 min. This is accompanied by
an increase of poly-OH-prog from 6% after 10 min to 26% after 60 min.
Etp1(516-618) from Schizosaccharomyces pombe, which exhibits 81% sequence iden-
tity to the shortened, yet fully functional Adx(4-108), is also highly similar in its
three-dimensional structure as the comparison of the high resolution crystal struc-
tures shows (see figure 3.8). Particularly in region around the iron-sulfur cluster
any substantial deviations of the protein backbone are absent. Our docking stud-
ies, however, showed that subtle structural differences in the Adx(4-108) prevent it
from adopting the same binding orientation to the cytochrome as it was found for
Etp1 (see figure 3.9). It turned out that the residues around position 14 and 41 of
Adx would sterically clash with the cytochrome. Furthermore, Tyr82 cannot form
hydrogen-bonds to the cytochrome, whereas the corresponding Phe82 of Etp1 forms
hydrophobic contacts, whereby penetrating deeply through the cytochrome’s sur-
face. There, residues Phe107, Pro359, and Leu356 encase the side chain of Phe82 (see
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Figure 3.6: Time-dependent in vitro conversion of progesterone by CYP106A2 and
Etp1(516-618)/AdR. Conversions were stopped after 1, 5, 10, 15, 30, 45, or 60 minutes;
dotted lines indicate polyhydroxylated progesterone products, grey lines indicate the main
product 15β-OH-P, dashed with single dot lines indicate other monohydroxylated proges-
terone products, dashed lines indicate the remaining substrate progesterone. Within 10
minutes of conversion, 95 % of the progesterone is converted and 79% of 15β-OH-P is
produced. The amount of 15β-OH-P increases slightly up to 81 %, as polyhydroxylated
products are stay between 11 % and 18 % total. Here, further monohydroxylated products
range at about 4 % over the time course of 60 minutes (taken from [81]).
figure 3.10). As a consequence the distance between the heme iron of the cytochrome
and the iron-sulfur cluster is substantially shorter in the complex with Etp1 (19 A˚)
than in that with Adx(4-108) (24 A˚). The experimentally observed hydroxylation
pattern of progesterone, in particular the formation of polyhydroxylated products,
requires the reorientation of mono-hydroxylated progesterone. To be able to dissect
this process of reorientation from that of the electron transfer by the ferrodoxins, we
performed molecular dynamics simulation of 15β-OH-progesterone in CYP106A2.
The correspoding results show that reorientation of the mono-hydroxylated product
occurs within less than 100 ns. These molecular movements lead to conformations
in which hydroxylation of other positions (11α-, 9α-, and 6β) are possible, assuming
that a distance of less than 5 A˚ between the respective carbon atom and the iron of
the heme is sufficiently close for reaction. To proof experimentally the influence of
the mode of ferredoxin binding regarding the electron transfer velocity, stopped-flow
measurements were performed. Differences in the reduction traces reflect the differ-
ent binding behavior that were indicated by the conversion analysis and molecular
docking calculations. The resulting apparent rate constants (kapp) were calculated
and are presented in table 3.1.
Applying the redox system of Etp1(516-618)/Arh1, the apparent rate constant is
0.34 s−1, whereas the combination of Adx(4-108) and AdR leads to a lower kapp of
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Figure 3.7: Time-dependent in vitro conversion of progesterone by CYP106A2 and
Etp1(516-618)/Arh1. Conversions were stopped after 1, 5, 10, 15, 30, 45, or 60 min-
utes; dotted lines indicate polyhydroxylated progesterone products, grey lines indicate
the main product 15β-OH-P, dashed with single dot lines indicate other monohydroxy-
lated progesterone products, dashed lines indicate the remaining substrate progesterone.
Progesterone conversion is almost complete after 15 minutes (1 % left). Most 15β-OH-P
(78%) is formed after 10 minutes, and slowly decreasing to 69 % within 60 minutes of
conversion (less than the combination of Etp1(516-618)/AdR, see fig. 3.6). The formation
of polyhydroxylated progesterone products is slowly increasing and ranging in between 24
% and 26 % after 60 minutes of conversion (higher than with the combination Etp1(516-
618)/AdR, see fig. 3.6). Formation of other monohydroxylated progesterone products
(than 15β-OH-P) remains at 4 % after 5 minutes of conversion time (taken from [81]).
Redox combinations kapp[s
−1]
Adx(4-108)/AdR 0.29176 ± 0.00107
Etp1(516-618)/Arh 0.34322 ± 0.00072
Table 3.1: Table 1: Apparent rate constants (kapp) for the reduction of CYP106A2 by
the two redox partner combinations Adx(4-108)/AdR or Etp1(516-618)/Arh using 400 µM
NADPH, 2 µM ferredoxin reductase (AdR or Arh1), and 20 µM ferredoxin (Adx(4-108)
or Etp1(516-618)) in syringe A and 2 µM CYP106A2 and 200 µM progesterone in syringe
B. The equations used to fit with the data points were: f(x) = a ∗ (1 − e − b ∗ x). The
given constants correspond to the respective b in the exponent of the equations (taken
from [81]).
0.29 s−1. This is in full agreement with the calculated shorter distance of the active
site of the ferredoxin Etp1(516-618) and CYP106A2 compared with Adx(4-108), as
well as the faster overall conversion of progesterone when using Etp1(516-618)/Arh1.
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Figure 3.8: Superimposition of AdX(4-108) to the obtained docking conformation of
Etp1 (violet), which has its FeS-cluster in closest distance to CYP106A2. The loops of
Adx (coral) around residues 14 and 41 would clash with the cytochrome (omitted for
clarity) (taken from [81]).
3.2 Discussion
As every cytochrome P450 is in need of electrons, the choice of the corresponding
redox partners is crucial for the proper function of CYPs [86]. However, not every
electron transfer protein chain is capable of delivering electrons to different CYPs.
Therefore, a universal redox system, being able to reconstitute the activity of a
majority of CYPs, is the ultimate goal of current investigations [11]. There is a
variety of parameters one should consider when looking for such a universal sys-
tem, for example expressability, (thermo-) stability or electron transfer rate. Also,
mutants of CYPs that show altered interaction sites to the ferredoxins could be a
way to change the substrate conversions. Pikuleva et al. [94] demonstrated that
a replacement exchanging conserved lysines with alanines at positions 354 and 358
of CYP27A1 within the presumed adrenodoxin-binding site resulted in an approx-
imately 20-fold increase in the apparent Ks values for adrenodoxin. In this study,
we had a closer look at redox systems from different organisms that have already
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Figure 3.9: Overlay of the energetically most favorable docking conformations of AdX(4-
108) and of Etp1 to CYP106A2. Adx (coral) is not able to bind in the same orientation
as Etp1 (violet) due to subtle but distinct structural differences (taken from [81]).
been used with diverse CYPs: Adx(wildtype), Adx (4-108) and AdR from bovine
origin, Etp1(516-618) and Arh1 from the yeast Schizosaccharomyces pombe, FldA
and Fpr from Escherichia coli, Fdx2 and BmCPR from Bacillus megaterium DSM
319, and YkuN from Bacillus subtilis 168. When looking for ideal redox part-
ners for CYPs, identification of an efficient redox system for a specific CYP should
be performed. This can be further optimized by methods of protein engineering
and finally tested with other CYP isoforms. As a first step to create a universal
redox system for CYPs, we tested the applicability of these diverse redox part-
ners to the well-studied CYP106A2 [27, 82, 25, 95, 30]. The experiments showed
clearly that all used combinations of redox partners were able to provide electrons
to CYP106A2. However, FldA and YkuN in combination with Fpr needed higher
ratios than the usual CYP:ferredoxin/flavodoxin:reductase ratio of 1:20:2 (figure
3.2). Only the truncated forms of Adx and Etp1, combined with AdR or Arh1,
were able to support CYP in a way that almost all provided progesterone (200 µM)
was converted within 30 minutes. Full-length Adx(1-128) as well as Fdx2 appeared
to have slower electron transfer rates towards CYP106A2 as their use results in 57
to 82 µM leftover substrate after 30 minutes of conversion. The selection of the
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Figure 3.10: Obtained docking conformation of Etp1 (violet) in which its FeS-cluster
is closest to the heme group of CYP106A2 (grey). Phe82 (cyan) penetrates into the
cytochrome forming hyrophobic contacts with Phe107, Pro359, and Leu356 (green) (taken
from [81]).
reductase in the redox system has also some influence on conversion as it affects
the overall turnover yield as seen with Etp1(516-618)/AdR (100%) compared with
Etp1(516-618)/BmCPR (79 %). The major, but most unexpected result testing
the electron transport ability of the different redox systems, was the observation
that the exchange of the redox partners resulted in variable product distributions.
The hydroxylation of progesterone by CYP106A2 reconstituted with the commonly
used redox system Adx(4-108) and AdR produces monohydroxylated progesterones
(15β-, 6β-, 9α-, and 11α-progesterone, 15β-OH-P being the main product of wild-
type CYP106A2) and polyhydroxylated progesterone products. When using this
“parent” system of Adx(4-108) and AdR for 30 minutes of conversion, 65 % of the
products are polyhydroxylated progesterones, 27 % are 15β-OH-P, 5 % are other
monohydroxylated progesterones, and 3 % is remaining substrate. This ratio dra-
matically changed when using Etp1(516-618) as ferredoxin instead of Adx(4-108)
which results in only 18 % poly-OH-P, 78 % 15β-OH-P, 3 % other monohydrox-
ylated progesterones, and 0 % remaining substrate. Similar results were obtained
when using full-length Adx(1-128) and AdR (where the formation of poly-OH-P al-
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most completely drops to 1% and 15β-OH-P is up to 53 %; but in this case, still 41
% of the substrate is not converted after 30 minutes) or Fdx2 and Arh1 (where 2 %
poly-OH-P and 66 % 15β-OH-P is produced, but 29 % substrate is not converted).
Obviously, in the later two cases the reaction rate is too slow to support further
hydroxylation of 15β-OH-P to polyhydroxylated products. To inspect the time
dependency of the product formation, the conversions by CYP106A2 with the com-
binations of Adx(4-108) or Etp1(516-618) with AdR or Arh1 were stopped after 1,
5, 10, 15, 30, 45, and 60 minutes (figures 3.4-3.7) to be investigated in detail. These
experiments show that the conversion of progesterone by the ferredoxins is typically
complete within 10 minutes (Etp1(516-618)/AdR) to 30 min (Adx(4-108)/AdR and
Adx(4-108)/Arh1). This proves a very efficient substrate conversion. The product
distribution, however, is varying heavily within the investigated time frame. While
the amount of 15β-OH-P is raising in every combination to at least 67 % within 5 to
10 minutes, it is afterwards dropping substantialy down to around 30 % when using
Adx(4-108). This harsh decrease is accompanied by a steep increase of poly-OH-P
up to 66 % (Adx(4-108)/Arh1). Using Etp1(516-618), the ratio of 15β-OH-P is ei-
ther decreasing only slightly after 10 minutes (with Arh1) or remains constant (with
AdR). Based on these results, it becomes clear that the different redox partner com-
binations tested here can be used for different purposes, depending on the overall
product yield and pattern one is aiming for. For approaches going for fast substrate
conversions, truncated versions of ferredoxin should be used as these are able to
process over 90 % of 200 µM substrate within 10 to 15 min to the corresponding
products. Adx(4-108) would be preferable to those aiming for many polyhydroxy-
lated progesterone products as with increasing conversion time one is able to obtain
almost 130 µM polyhydroxylated progesterone products out of 200 µM substrate
(59 % conversion). Polyhydroxylated products can be of big interest, because they
represent a high diversity and, therefore, different possibilities for further alteration
of the steroid molecule. Since many attempts are focussed on high yields of certain
monohydroxylated products, application of truncated Etp1(516-618) is useful to ob-
tain high absolute and relative yields (shown here for the main product 15β-OH-P)
within only 5 minutes. The least percentage of polyhydroxylated progesterones af-
ter 30 minutes was found with the redox partner system FldA/Fpr. However, the
facts that only a ratio of CYP106A2/FldA/Fpr of 1:50:50 was able to hydroxlate
progesterone and that only 27 % of product were found, characterize this system as
low efficient. Systems using Adx(1-128) as redox partner are further candidates for
the production of monohydroxylated progesterones because they produce only 1%
of polyhydroxylated products. However, also in this case, the activity is rather low
(max. 62 % conversion after 30 minutes). A longer conversion time (60 minutes)
is increasing the overall product yield (data not shown). As almost every redox
partner combination alters the product pattern of the conversion of progesterone
by CYP106A2, the comparison especially of the ferredoxins as the direct electron
transfer proteins to CYP106A2 is of interest. The crystal structures of the bovine
Adx(4-108) and the yeast Etp1(516-618) have been solved by Mu¨ller [96, 40] and
an evaluation of differences and similarities is, therefore, possible. Both enzymes
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show an amino acid identity of 46 %, with overall highly conserved regions. Despite
the similarity, there are also some differences: The thermal transition temperature
Tm of Etp(516-618) is 65
◦C, about 14 ◦C higher than the Tm of Adx(4-108) of 51
◦C [40]. When comparing protein-protein dockings of Adx(4-108) or Etp1(516-618)
and CYP106A2 (fig. 3.8), different binding modes of the chosen ferredoxins become
obvious: Adx(4-108) prefers binding close to the heme using a different interaction
region compared with Etp(516-618) (see figs. 3.8 and 3.9). Phe82 of the Etp1(516-
618) is in a sandwich position with Phe107, Pro359, and Leu356 of the CYP106A2
and enables Phe82 to come close to the heme (see fig. 3.10). In contrast, Tyr82 of
Adx(4-108) does not bind to the CYP, because the corresponding orientation is ster-
ically hindered by the residues Arg14 and Asp41, as they would clash with the CYP.
On the basis of the possible orientations, the calculated distance between the FeS-
Cluster and the heme-iron atom is longer (24 A˚) for the binding of the Adx(4-108)
than for Etp1(516-618) (19 A˚) in the closest conformation found, respectively. This
condition allows Etp1(516-618) to approach closer and, therefore, enables faster elec-
tron transfer. On the other hand, the binding of the Adx(4-108) could be stronger
than that of Etp1(516-618), for example due to larger electrostatic contributions,
resulting in a slower release of Adx(4-108). This may lead to a longer disposition of
the substrate in the active site of the CYP106A2 and, therefore, also more than one
single hydroxylation product. This can be caused by the kind of contact between the
ferredoxin and the CYP, meaning an intense binding and slow transfer of electrons
could not allow the then-build product to exit the active site of the CYP, reverse
that a looser binding and fast e-transfer is enabling the monohydroxylated proges-
terone to leave the binding pocket before further hydroxylation is performed. In the
absence of experimental data on the actual life time of these transient complexes
between the respective ferredoxins and the CYP, corresponding assumptions must
be considered with some care. Nevertheless, our molecular dynamic simulations of
15β-OH-progesterone in the binding pocket of CYP106A2 show that reorientation
of the mono-hydroxylated product occurs within 100ns, leading to conformations
in which hydroxylation of other positions (11α-, 9α-, and 6β) is likely. This time
scale is rather fast compared to that of the product release, which was not observed
within the simulation time of 200 ns. Thus, the observed product spectra are gov-
erned by several factors, which are not independent of each other. Taken together,
our results demonstrate that different aspects play a role when a decision has to be
undertaken which redox system is the most preferable one for a certain cytochrome
P450. We were able to show that the use of different redox systems manipulates
the rate and the yield of conversion of progesterone by CYP106A2. Also product
distribution by changing the redox partners can be altered between high levels of
polyhydroxylated or monohydroxylated progesterone products. The application of
the Schizosaccharomyces pombe Etp1(516-618) results in high quantity of the main
monohydroxylated product, achieving 155 µM 15β-OH-P out of 200 µM substrate
(78 %) within 30 minutes of conversion, whereas the bovine Adx(4-108) produces
many polyhydroxylated progesterone products (129 µM or 65 %). Working with the
full-length Adx(1-128), one gets high amounts of monohydroxylated progesterone
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products (113 µM) with the downside of a slow conversion (only 59 %). These ex-
perimental data were supported by molecular docking revealing a shorter distance
between the FeS-cluster of the ferredoxin and the CYP heme for Etp1(516-618) than
for Adx(4-108). Backing the molecular docking data, it was shown by stopped flow
measurements that the apparent rate constant (kapp) of Etp1(516-618)/Arh1 was
higher than that of Adx(4-108)/AdR, therefore resulting in a faster electron transfer
between Etp1(516-618) and CYP106A2 than between Adx(4-108) and CYP106A2,
explaining the above mentioned product pattern in conversions with progesterone.
Assuming a longer life time of the complex (Adx(4-108) with CYP106A2, the mono-
hydroxylated products are able to reorient more often applying Adx(4-108) than
Etp1(516-618) resulting in more hydroxylations and, therefore, higher amounts of
polyhydroxylated products. This knowledge can be employed to modify or tune the
amount of the given products. Thus, applying the studied redox systems from bac-
terial, fungal, and mammalian origin, various effects on the product patterns have
been observed and are promising for tuning biotechnological reactions for different
purposes.
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Chapter 4
Engineering of CYP106A2 for
steroid 9α - and 6β-hydroxylation
The results and discussion section (4.1), the conclusion section (4.2) as well as figures
4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8 and tables 4.1, 4.2, 4.3 were adapted unaltered
from our publication [55], whereas the experimental section is omitted here.
Bacillus megaterium cytochrome CYP106A2 also known as 15β-hydroxylase is a
very interesting target for biotechnological applications due to its broad range of
steroid acceptance. In past experiments directed evolution or site-directed mutage-
nesis were successfully applied. In publications from Lisurek et al [82, 97] CYP106A2
was engineered towards the conversion of progesterone. The main product was 15-
OH-progesterone but side products were also found namely 6β-, 9α- and 11α-OH-
progesterone (which were not only monohydroxylated but also di- and polyhydroxy-
lated; fig. 4.1). Exchange of the amino acids T89N/A395I and A160T/A395I/R409L
lead to an increase of 11α-OH-progesterone from 27.7% to 80.9% while produc-
tion of 15β-OH-progesterone decreased from 50.4% to just 4.8% with a mutation of
T89N/A395I [98]. 11α-OH-progesterone is a very interesting candidate for the phar-
maceutical application. Not only does it exhibit an antiadrenogenic activity with
minimal estrogenic or progestional side effects [99, 100] but also influences blood
pressure through selective inhibition of 11β-hydroxysteroid dehydrogenase type 2
[101, 102]. Additionally 11α-OH-progesterone serves as a substrate for cortisone
and hydrocortisone production [103, 104]. 6β-OH-progesterone was proven to be
an intermediate for inhibitors of growth of breast cancer cells [105] and inhibits 5α
reductase activity in male rat liver microsomes [106]. 9α-OH-progesterone serves
also as an important intermediate for a substrate that exhibits glucocorticoid and
progestional activity [82, 107].
Due to complicated reaction processes in chemical synthesis of this compounds a
biotechnological synthesis is favored. Changing the selectivity of natural CYP106A2
with site-directed mutagenesis or directed evolution towards a 9α- or 6β-OH-
progesterone smooth the way for biotechnological production of pharmaceutical
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Figure 4.1: CYP106A2-catalyzed conversion of progesterone to 15β-, 11α-, 9α- and
6β-hydroxyprogesterone (taken from [55]).
compounds and industrial application of the enzyme.
This study describes the engineering of CYP106A2 towards the production of 6β-
as well as 9α-hydroxyprogesterone. The mutant proteins were selected from a satu-
ration mutagenesis library with performing a site-directed mutagenesis of them. For
9α-hydroxylase activity a 11-fold increase compared to the wild type (WT) could
be measured, using a whole cell system. During the studies a first crystal structure
for CYP106A2 was published [30] which allowed for docking experiments of pro-
gesterone to variants of CYP106A2 that would change the selectivity from 15β- to
6β-OH-progesterone. Our former docking experiments show two different conforma-
tions. One that allows for a 15β- or 6β hydroxylation and an other one that makes
the α-positions accessible. For the latter the [C3 = O] bond builds a hydrogen bond
with threonine at position 247. Therefore we proposed three different mutations:
Threonine at position 247 to alanine
Breaks hydrogen bond at position 247 and makes alternative conformation
more likely
Alanine at position 243 to serine
Stabilizes alternative conformation by creating hydrogen bond with [C20 = O]
Phenylalanine at position 173 to alanine
Creates more space above heme group to place progesterone more ”optimal”
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4.1 Results and Discussion
The bacterial enzyme CYP106A2 was regarded as suitable platform to change the
steroid hydroxylation regioselectivities and to improve the catalytic efficiencies of
the obtained mutant proteins. Therefore, a library of CYP106A2 with different mu-
tations, containing more than 13000 clones was created based on the replacements
at positions A395 and G397 by a combination of site-directed and saturation muta-
genesis of active site residues, followed by several rounds of site-directed mutagenesis
based on a low-homology model of CYP106A2 [98, 108]. The library was screened
using 200 µM progesterone as a substrate followed by HPLC to identify mutant pro-
teins with increased 9α-hydroxylase activity. Sixteen mutant proteins with improved
activity were selected from this library. HPLC analysis identified the yields of 15β-,
11α-, 9α- and 6β-hydroxyprogesterone for each mutant protein (table 4.1). In ad-
Nr Mutation 15β-OH-P [%] 11α-OH-P [%] 9α-OH-P[%] 6β-OH-P [%]
WT 67.9 18.0 5.4 8.7
1 A395T/G397K 11.2 20.0 45.1 23.7
2 A395H/G397Y 22.9 15.2 38.6 23.3
3 A395I 28.7 50.9 10.2 10.2
4 A395E/G397V 9.4 15.9 48.6 26.1
5 A395R/G397K 9.1 12.9 44.8 33.2
6 A395M/G397S 13.1 65.6 14.4 6.9
7 A395R/G397I 13.2 12.7 47.0 27.2
8 A395R/G397P 38.4 57.0 2.4 2.2
9 A395K 16.5 37.2 42.4 4.0
10 G397W 27.3 36.4 27.3 9.1
11 A395F 32.5 38.3 11.5 17.7
12 A243V 78.0 8.2 3.6 10.2
13 A395W/G397K 10.5 19.2 55.9 14.3
14 A395E/G397Stop 13.4 15.5 45.4 25.8
15 A395S/G397Y 18.5 13.7 41.1 26.8
16 A395R/G397R 8.8 14.9 45.8 30.6
Table 4.1: Progesterone hydroxylation catalyzed by CYP106A2. Relative values of the
product pattern (15β-, 11α-, 9α- and 6β-hydroxyprogesterone) after 24 h in vivo con-
version of 200 µM progesterone catalyzed by wild type CYP106A2 and its 16 mutant
proteins, which were selected from a library. Values show percentages with the sum of all
monohydroxylated products set as 100% (taken from [55]).
dition to the single-hydroxylated products in dependence on the reaction time also
small amounts of di- and polyhydroxylated products were formed (data not shown).
Ten mutant proteins formed 9α-hydroxyprogesterone as a main product. It can be
seen from table 4.1 that CYP106A2 A395W/G397K showed the highest (55.9%)
and A395H/G397Y, respectively, the lowest (38.6%) 9α-hydroxyprogesterone for-
mation. This comprises an at least 8-fold improvement compared to the wild
type. In contrast, CYP106A2 A395R/G397R possessed the greatest decrease of
15β-hydroxylase activity, from 67.9% to 8.8%. The other six mutant proteins
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(A395I, A395M/G397S, A395R/G397P, G397W, A395F and A395V) exhibited a
smaller 9α-hydroxylase activity compared to A395W/G397K and A395H/G397Y,
whereby two mutant proteins (A395R/G397P and A243V) showed almost no 9α-
hydroxyprogesterone formation at all. In addition, A243V showed a higher selectiv-
ity towards 15β-hydroxyprogesterone formation compared to the wild type enzyme.
The four best mutant proteins A395E/G397V, A395R/G397K, A395W/G397K, and
A395R/G397R with the highest 9α-hydroxyprogesterone formation were selected
for further mutation via site-directed mutagenesis to improve their regioselectiv-
ity. Therefore, seven single replacements (D217V, A243V, A106T, F165L, T89N,
T247V and T247W) were inserted into the four mutant proteins. These mutations
were shown before to influence the regioselectivity and catalytic efficiency in a pos-
itive way. Rauschenbach and Virus could show that they exhibit higher turnover
rates towards progesterone conversion compared to the wild type [109, 95]. In ad-
dition, it was reported that the highly conserved threonine residue in the I-helix of
the active side near the heme of P450s directly affects the catalytic efficiency due
to its participation in the proton shuttle which is important for proton delivery and
molecular oxygen activation [97]. Therefore, the mutations T247V and T247W were
also carried out. The insertion of these seven amino acid replacements into the four
“parent mutant proteins” led to 28 new mutant proteins that were also tested for in
vivo conversion of 200 µM progesterone, respectively. Five mutant proteins showed
almost no conversion. Due to their low activity, these clones were not followed up
in further experiments. Sixteen mutant proteins possessed a 9α-hydroxylase activ-
ity similar to that of the parent mutant proteins. There were also two mutant
proteins (A243V/A395E/G397V and T89N/A395W/G397K) with a strong shift
in regioselectivity, but they also showed an increase in di- and polyhydroxylated
progesterone. These products were observed in the HPLC chromatograms (be-
tween 3.5 and 7.5 min) with the peak size depending on the conversion time as
well as the corresponding mutant protein. By shortening the reaction time, the
amounts of side product can be reduced [98]. Interestingly, five mutant proteins dis-
played a low amount of di- and polyhydroxylated progesterone and conversely a high
amount of 9α-hydroxyprogesterone (D217V/A395E/G397V, F165L/A395E/G397V,
A106T/A395R/G397K, A243V/A395R/G397R and A106T/A395R/G397R) (fig
4.2). The relative amounts of hydroxylated metabolites after conversion of
progesterone in the presence of the best five of the 28 mutant proteins of
CYP106A2 are shown in table 4.2. CYP106A2 F165L/A395E/G397V had
the strongest shift in the regioselectivity showing a formation of 59.7% 9α-
hydroxyprogesterone. This represents an improvement of the yield of 9α-
hydroxyprogesterone by 15% compared to the initial CYP106A2 A395E/G397V,
but a 12-fold improvement compared to the wild type CYP106A2. In turn, the
amount of 15β-hydroxyprogesterone decreased from 67.9% to 11.3%. Mutant pro-
teins D217V/A395E/G397V, A106T/A395R/G397K, and A106T/A395R/G397R
showed a shift in regioselectivity of about 10% compared to the parent mutant
proteins A395E/G397V, A395R/G397K, and A395R/G397R, respectively, and of
about 51% compared to the wild type. CYP106A2 A243V/A395R/G397R pos-
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Figure 4.2: HPLC analysis of the in vivo conversion of 200 µM progesterone
by wild type CYP106A2 (A) and the mutant proteins D217V/A395E/G397V(B),
F165L/A395E/G397V (C), A106T/A395R/G397K (D), A243V/A395R/G397R (E),
A106T/A395R/G397R (F). The figure shows di- and polyhydroxylated(6) and monohy-
droxylated products (15β- (1), 11α- (2), 9α- (3) and 6β-hydroxyprogesterone (4)), as well
as the substrate progesterone (5). HPLC analysis was performed with H2O:ACN (90:10)
as a mobile phase and a CC 125/4 nucleodur 100-5 C18 ec column at 40 ◦C (taken from
[55]).
Mutation 15β-OH-P [%] 11α-OH-P [%] 9α-OH-P[%] 6β-OH-P [%] P[%]
WT 67.9 18.0 5.4 8.7 0.0
D217V/A395E/G397V 7.5 23.2 55.9 7.9 5.4
F165L/A395E/G397V 11.3 17.2 59.7 11.0 0.9
A106T/A395R/G397K 13.0 22.4 57.4 6.8 0.4
A243V/A395R/G397R 11.8 17.6 49.7 8.3 12.7
A106T/A395R/G397R 12.9 14.9 56.2 13.3 2.7
Table 4.2: Selection of progesterone hydroxylation catalyzed by improved mu-
tated CYP106A2. Relative values in % of progesterone and the monohydroxy-
lated products 15β-, 11α-, 9α- and 6β-hydroxyprogesterone after 24 h in vivo con-
version of 200 µM progesterone catalyzed by wild type CYP106A2 and the mu-
tant proteins D217V/A395E/G397V, F165L/A395E/G397V, A106T/A395R/G397K,
A243V/A395R/G397R and A106T/A395R/G397R, respectively. Values show percent-
ages with the sum of the substrate progesterone and all monohydroxylated products set
as 100% (taken from [55]).
sessed the smallest enhancement of 9α-hydroxyprogesterone formation (49.7%), but
a large decrease of 15β-hydroxyprogesterone from 67.9% to 11.8% compared to the
CYP106A2 wild type. Taken together, this data clearly demonstrate that using a
combination of site-directed mutagenesis/saturation mutagenesis not only changes
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the selectivity from the 15β- to the 11α-position of progesterone as described be-
fore, [98] but this approach can also be applied to change the regioselectivity of
progesterone hydroxylation from position 15 in the D ring to position 9 in the B
ring. For creating mutant proteins leading to 6β-hydroxyprogesterone production,
the recently solved crystal structure of CYP106A2 was used [30]. After performing
docking of progesterone into this structure, several amino acids in the enzyme were
identified, whose mutation should lead to a change in the selectivity from 15β to
the 6β position leading to the production of 6β-hydroxyprogesterone. It was sug-
gested that the change from threonine to alanine at position 247 should interrupt
a hydrogen bond, which should then prefer an alternative conformation of the sub-
strate within the active site. Moreover, serine instead of alanine in position 243
was expected to stabilize a corresponding conformation in which 6β hydroxylation
is favored by introducing a new hydrogen bond with the carbonyl oxygen in posi-
tion 21 (fig. 4.3). To support this assumption, we carried out molecular dynamics
simulations of progesterone in a homology model of this CYP106A2 A243S. Fig.
4.4 and fig. 4.5 show the time course of the distances of the hydrogen atoms in
15β and 6β position from the iron atom of the heme group, respectively. Whereas
both curves show a decrease of the distance from the beginning of the simulation to
about 5 ns, the 6β position remains closer to the heme iron within the subsequent
5 ns. The shortest distance for the 15β position was observed after 19.2 ns (2.6 A˚),
whereas the minimum distance of the 6β position was found already after 6.8 ns (3.0
A˚). Likewise, the average distances are 5.7 and 5.5 A˚, respectively, over the total
simulation time of 20 ns. The maximum distances were seen rather early between
0.5 and 3.0 ns, both being beyond 9.2 A˚. Obviously this short time span of 5 to
10 ns in which the 6β position is about 1 A˚ closer to the heme iron than the 15β
position seems to determine the product spectrum. Finally, changing phenylalanine
against the smaller alanine at position 173 should create more space over the heme
for an optimal conformation of progesterone for 6β-hydroxylation. Single mutations
as well as combinations of these three changes were inserted into CYP106A2. The
obtained mutant proteins were used for the conversion of progesterone. CYP106A2
F173A/T247A did not show any significant conversion, whereas mutant proteins
F173A, T247A, A243S/T247A and F173A/A243S converted progesterone to the
main product 9α-hydroxyprogesterone. However, CYP106A2 with the replacements
A243S and F173A/A243S/T247A, respectively, showed 6β-hydroxyprogesterone as
main product with a 9- and 6-fold improvement, respectively, compared to the wild
type. The amount of other products, 15β-, 11α- and 9α-hydroxyprogesterone, of
CYP106A2 A243S is much lower than that of the triple mutant protein (table 4.3).
Fig. 4.6 shows the chromatogram of CYP106A2 A243S compared to the wild type.
It can be seen that site-directed mutagenesis of CYP106A2 based on the results of
docking of progesterone into the crystal structure of this protein, led to a nearly
complete change of the regioselectivity of hydroxylation from the 15β- to the 6β-
position, i.e. from the D-ring to the B-ring. More than 80% 6β-hydroxylation was
obtained. To find out whether mutant proteins, which are changing the regioselec-
tivity of progesterone hydroxylation from the 15 to the 11, 9, or 6 position, show
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Figure 4.3: Docking of progesterone into the X-ray structure of wild-type CYP106A2
showed position 15β (orange) being closest to the heme iron (3.9 A˚). However, hydroxy-
lation was experimentally also observed in 6β position (purple) (5.1 A˚). The replacement
of alanine by serine in position 243 would enable a new hydrogen-bond (blue dotted line)
to the carbonyl oxygen in position 21. As a further consequence the progesterone is
also shifted towards this residue thereby bringing position 6β in closer contact to the
heme iron. The corresponding mutant protein shifted the main product from 15β to
6β-hydroxy-progesterone (taken from [55]).
another substrate space than the wild type, a natural product library was screened
with CYP106A2 T89N/A395I [98], F165L/A395E/G397V, and A243S, respectively.
Screening of the library with these three mutant proteins showed the same twelve
compounds as already published by Schmitz et al. [29] for wild type CYP106A2 so
that obviously no change in the substrate space occurred. To investigate a possible
change in the regioselectivity of other known CYP106A2 substrates, dipterocarpol
was converted with the three mutant proteins and the results were compared to those
of the wild type, which formed two products, 7β-hydroxydipterocarpol and 7β, 11α-
dihydroxydipterocarpol. Interestingly, the three mutant proteins converted dipte-
rocarpol only into one product, 7β-hydroxydipterocarpol, indicating an increased
specificity of hydroxylation towards the 7β-position. Fig. 4.7 shows exemplarily
the thin layer analysis of CYP106A2 T89N/A395I. Finally, 11-deoxycorticosterone,
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Figure 4.4: Time course of the distance (given in A˚) between the hydrogen atom in
position 15β of progesterone and the iron atom of heme of the heme group during a 20 ns
molecular dynamic simulation of CYP106A2 A243S (taken from [55]).
was converted in vivo in the presence of wild type CYP106A2 and the six best mu-
tant proteins created in this work (D217V/A395E/G397V, F165L/A395E/G397V,
A106T/A395R/G397K, A243V/A395R/G397R or A106T/A395R/G397R, A243S).
Fig. 4.8 shows the HPLC chromatogram of the conversion of DOC with wild type
CYP106A2 and with CYP106A2 A106T/A395R/G397R. The wild type produced
15β-hydroxy-DOC as the main product as well as 6β-hydroxy-DOC and 7β, 15β-
dihydroxy-DOC as minor products [110]. In case of the mutant proteins the peaks
2 (7β, 15β-dihydroxy-DOC) and 3 (15β-OH-DOC) drastically decreased whereas
peak 4 was enhanced, demonstrating an increased production of 6β-OH-DOC. To
date product 1 has not been identified because the amount is not sufficient for
NMR analysis. We assume that this peak comprises either a mixture of several
monohydroxylated DOC products or di- and/or polyhydroxylated DOC. Taken to-
gether, it can be concluded that the mutations introduced by directed evolution
and site-directed mutagenesis led also to a change in the regioselectivity of other
steroidal substrates besides progesterone resulting in an increase in the selectivity of
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Figure 4.5: Corresponding time course of the distance for the hydrogen atom in position
6β of progesterone. Between 5 and 10 ns this position is about 1 A˚ closer to the heme iron
atom and was experimentally found to be the main hydroxylation product of CYP106A2
A243S (taken from [55]).
dipterocarpol hydroxylation towards the 7β position and in the new main product
6β-hydroxy-DOC instead of 15β-hydroxy-DOC. The strongest shift in selectivity
towards DOC hydroxylation was shown by CYP106A2 D217V/A395E/G397V dis-
playing an improvement of 6β-OH-DOC by 44% and, on the other hand, showing a
decrease of 15β-OH-DOC by 36% compared to CYP106A2 wild type.
4.2 Conclusion
In this work we were able to demonstrate that a combination of site-directed mu-
tagenesis and saturation mutagenesis of CYP106A2 is able to influence the regios-
electivity of progesterone hydroxylation, shifting it from C15 in the D ring to C9
and to C6 in the B ring, respectively. Besides changes in the regioselectivity, also
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Mutation 15β-OH-P [%] 11α-OH-P [%] 9α-OH-P[%] 6β-OH-P [%] P[%]
WT 67.9 18.0 5.4 8.7 0.0
F173A 9.7 32.5 44.1 5.0 8.6
A243S 3.4 4.6 2.4 82.7 6.9
T247A 11.7 13.1 45.7 24.3 5.3
F173A/A243S 12.5 15.5 51.8 15.9 4.3
A243S/T247A 14.6 13.2 48.0 20.7 3.4
F173A/A243S/T247A 13.6 6.5 8.7 57.2 19.1
Table 4.3: Progesterone hydroxylation catalyzed by improved mutated CYP106A2.
Relative values in % of progesterone as well as the monohydroxylated products 15β-
, 11α-, 9α- and 6β-hydroxyprogesterone after 24 h in vivo conversion of 200 µM
progesterone by wild type CYP106A2 and the mutant proteins F173A, A243 S,
T247A, F173A/A243S, A234S/T247A and F173A/A243S/T247A, F165L/A395E/G397V,
A106T/A395R/G397K, A243V/A395R/G397R and A106T/A395R/G397R, respectively.
Values show percentages with the sum of the substrate progesterone and all monohydrox-
ylated products set as 100 % (taken from [55]).
a change in the stereo-selectivity from the 15β to the 9α position was obtained.
It was shown that the hydroxylation position in the steroid depends on the mu-
tation introduced into the protein. Whereas mutant proteins with a change in
the selectivity from 15β- to 11α-hydroxyprogesterone as described previously [98]
showed the largest shift in mutant proteins A106T/A395I, A106T/A395I/R409L,
and T89N/A395I, CYP106A2 F165L/A395E/G397V demonstrated the strongest
shift from the 15β towards 9α position. Interestingly, a nearly complete shift in
the regioselectivity of progesterone hydroxylation from the 15β to the 6β position
was obtained with CYP106A2 A243S, which was constructed by rational protein
design/site-directed mutagenesis based on the recently available X-ray structure of
the wild type [98]. In addition, we were able to demonstrate that also other steroids
similar to progesterone, such as DOC and dipterocarpol, are hydroxylated with
changed selectivity when using the above mentioned mutant proteins. Finally, the
approach described here, especially when using the 3D structure of CYP106A2 as
a basis for the rational design of mutant proteins, leads to desired changes in the
regio- and stereo-selectivity of progesterone hydroxylation. The obtained products,
9α- and 6β-hydroxyprogesterone, are of biotechnological importance for a sustain-
able production of pharmaceutically valuable compounds.
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Figure 4.6: HPLC analysis of the in vivo conversion of 200 µM progesterone by wild type
CYP106A2 and with the mutation A243S. The figure shows di- and polyhydroxylated (6)
and monohydroxylated products (15β- (1), 11α- (2), 9α- (3) and 6β-hydroxyprogesterone
(4)). Product 5 only appears in the mutant protein and was not identified yet. HPLC anal-
ysis was performed with H2O:ACN (90:10) as a mobile phase and a CC 125/4 nucleodur
100-5 C18 ec column at 40 ◦C (taken from [55]).
48 CHAPTER 4. ENGINEERING OF CYP106A2
Figure 4.7: Thin layer analysis of the in vivo conversion of 200 µM dipterocarpol by wild
type CYP106A2, the CYP106A2 T89N/A395I and a control without any enzyme. The
figure shows the two products, 7β-OH-dipterocarpol and 7β,11α-OH-dipterocarpol. Thin
layer analysis was performed with hexane/EE 1:1 as a mobile phase (taken from [55]).
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Figure 4.8: HPLC analysis of the in vivo conversion of 200 µM DOC by wild type
CYP106A2 and with the mutation A106T/A395R/G397R. The figure shows the products
15β-OH-DOC (3), 6β-OH-DOC (4) and 7β,15β-dihydroxy-DOC (2), as well as the sub-
strate DOC (5). Due to the small amount product 1 is not identified yet. HPLC analysis
was performed with H2O:ACN (60:40) as a mobile phase and a CC 125/4 nucleodur 100-5
C18 ec column at 40 ◦C (taken from [55]).
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Chapter 5
Rational Design of Mutants that
Lower the Redox Potential of
Bovine Adx
In this study we dealt with new ways towards implementing a system to check the
influence of an amino acid exchange on the redox potential of Adx. We were also
able to give proof how the redox potential is affected in the Adx deletion mutant
T∆49. More precisely what the distortion of the iron-sulfur cluster accounts for.
Experimental validation for our suggested amino acid exchange still needs to be
performed. The difficulties in computing redox potentials for ferredoxins like Adx
is to account for the structural change upon reduction of the iron-sulfur cluster.
Unfortunately, no conclusive information regarding the iron-sulfur cluster and its
proximity is available from NMR measurements, because this region is blurred due
to the paramagnetic properties of the reduced state. Moreover, the geometry of the
iron-sulfur cluster was assumed to be fixed. Existing quantum chemical calculation
on model systems of the iron-sulfur cluster, however, strongly suggest that the iron-
iron distance increases in the reduced state, independently of the density functional
being used [111, 112]. This can be attributed to the fact that the iron-sulfur cluster
compensates the increased electron density by a distinct expansion. Bernhardt and
coworkers studied a series of Adx mutants and collected experimental data regarding
their catalytic activity [113]. They observed that mutants with lower redox potential
than the wild-type showed increased values of kcat. In particular, the T49∆ mutant
where threonine at position 49 was deleted, exhibited the most pronounced increase
of KM that goes along with a decrease of -87 mV (0.087 eV) of the redox potential,
whereas all other exchanges of single amino acids did not lead to similar strong effects
[114]. Substantial decrease of the redox potential was also observed for deletions of
multiple residues at the C-terminal end, e.g. those beyond position 108, which do not
seem to be necessary for the function. Moreover, residues above position 112 were
not resolved in the above mentioned X-ray structures, suggesting increased flexibility
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and the absence of secondary structural elements. So far, no systematic study to
elucidate the underlying mechanisms that influence the redox potential by the above
mentioned mutations has been carried out, although theoretical approaches have
been presented, which account for mutations of single amino acids [56].
5.1 Theoretical Background
Experimentally, the redox potential E0 is measured in comparison to a reference
potential applying a dye photoreaction, whereby Safranin T functions serves both
as indicator and mediator [113]. Using Nernst’s equation the free energy ∆G of the
reduction process for Adx is thus the difference in solvation energy ∆Gsolv between
the reduced and the oxidized protein plus the absolute potential of the standard
hydrogen electrode ESHE, whereby ESHE = 4.44 ± 0.02 V (eq. 5.1):
∆G = −zGE0 = ∆Gsolv + FESHE (5.1)
Here, z = 1 since only one electron is transferred, and F is the Faraday constant. In
more detail the change in solvation energy comprises the change of the inner-sphere
energy ∆Gin due to the different electron configuration, which is mainly localized
on the iron-sulfur cluster, and the change of the outer sphere energy ∆Gout that
arises from conformational changes of the surrounding protein (eq. 5.2):
∆Gsolv = ∆Gin + ∆Gout (5.2)
The change in inner-sphere energy ∆Gin corresponds to the adiabatic gas phase
ionization potential of the reduced iron-sulfur cluster IPred, which can be computed
from density functional calculations [111]. Most of the known mutations of bovine
Adx comprise exchanges of a single amino acid on its surface or deletions at the
N-terminal part, respectively the C-terminal part that are unlikely to change the
local geometry of the iron-sulfur cluster [113]. Therefore ∆Gin, respectively IPred
can be assumed to be the same for the wild-type and these mutants, whereas the
major difference that causes the altered redox potential arises from ∆Gout. However
for mutants that induce a drastic conformational change to the geometry of the
iron-sulfur cluster, i.e. the T49∆ mutant, which leads to the rearrangement of the
side chain of Cys46, a substantial fraction of the observed change in redox potential
is likely to arise from the change of IPred . So far, no corresponding investigation
of this effect has been carried out. To explain the underlying electrostatic interac-
tions that eventually give rise to the alterations in energy of iron-sulfur proteins,
respectively the redox potential of mutants, several theoretical approaches have been
applied: Poisson-Boltzmann theory requires the accurate three-dimensional struc-
ture representation of both the oxidized as well as the reduced Adx solution, along
with appropriate assignment of atomic charges and protonation states for each amino
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acid [111, 115]. Furthermore, a lower dielectric constant can be used for the region
of the iron-sulfur cluster than for the surrounding protein [116]. Much earlier, Churg
and Warshel applied the protein dipoles-Langevin dipoles model to compute differ-
ences in solvation energy, whereby a similar finite grid was used [117]. Related to
both methods is the work of Ichiye and coworkers that makes use of the electrostatic
potential [118]. An intriguingly simple approach to explain the effect of single point
mutations was presented by Zhou [56]. Here, the protein (Adx) is treated as sphere
embedded in a medium of high dielectric constant (water), similar to the Tandford
and Kirkwood theory of solvation. The iron-sulfur cluster is represented as point
charge and the respective amino acid by its resulting dipole vector (fig. 5.1). Ac-
cording to this approach the change in redox potential depends on the orientation of
the dipole vector of this particular residue with respect to the vector that connects
the amino acid with the iron-sulfur cluster, as well as the corresponding distance
and the dielectric constant where the residue is located. In cases where mutations
of amino acids on the protein surface are carried out, the expected changes in redox
potential should therefore be minor, because polar or charged side chains are fully
solvated and thus effectively shielded by water due to its high dielectric constant.
Conversely, the change in redox potential is strongest, if buried residues in close
vicinity of the iron-sulfur cluster are exchanged, since they are now in the same
medium of low dielectric constant. If the resulting dipole vector points towards the
cluster an increase of the redox potential is expected and conversely a decrease if the
dipole vectors points away. In cases where the dipole vector is almost perpendicular
to the connecting vector (α around 90◦), only a marginal effect is predicted. Accord-
ing to Zhou, the contribution Ei of the considered residue i to the redox potential
is given as (eq. 5.3):
Ei ≈ e ·µ · r
p · r3
(5.3)
containing the scalar product of µ (dipole vector of residue i) and r (vector connect-
ing residue i and the iron-sulfur cluster). This term is multiplied by the electron
charge e and divided by the third power of the distance of vector r times the di-
electric constant of the protein p, which is around four and thus much smaller than
that of the aqueous surrounding s. From these physical considerations it transpires
that for the rational design of mutants with altered redox potential two factors are
important: First, the location of the particular amino acid should be close to the
iron-sulfur cluster and not on the protein surface, and second, the orientation of its
dipole vector is crucial. The required three-dimensional atomic coordinates of the
mutated amino acid can be obtained from corresponding homology models of the
wild-type Adx.
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Figure 5.1: The redox protein is approximated as sphere of low dielectric constant P
surrounded by water. Mutation of amino acids on the protein surface do not change the
redox potential notably, because their charges are strongly shielded from those of the iron-
sulfur cluster due to the much larger S of the solvent. The changes are expected to be
most pronounced if the mutated residue is buried inside the protein (same low dielectric
constant) and its dipole vector µ either points towards the iron-sulfur cluster (α  90◦,
leading to an increase of the redox potential), or pointing away (α  90◦, decrease of the
redox potential), whereas a perpendicular orientation (α ≈ 90◦) would cause the scalar
product between µ and r to vanish (see theory section for details)
5.2 Computational Methods
5.2.1 Density Functional Calculations
In order to obtain an estimate of the electronic reorganization energy upon reduc-
tion of the iron-sulfur cluster, we generated model systems of the Adx wild-type and
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of the corresponding T49∆ mutant that were used in subsequent density functional
calculations. For the model of the Adx wild-type the initial atomic coordinates of
the Fe2S2(SCH2CH3)4 fragment were taken from the crystal structure of bovine
Adx (pdb entry 1AYF, chain B). The positions of the carbon atoms correspond to
those of the Cβ and Cα atoms of the four ligating cysteines, respectively. The start-
ing geometry for the same fragment of the T49∆ mutant was taken from a homology
model of bovine Adx as obtained from the SWISS-MODEL server [119, 120]. The
deletion of threonine in position 49 causes a structural rearrangement that affects
residues 46-50, whereby the side chain of Cys46 is one of the four cysteines that
ligate the iron-sulfur cluster. Both model systems were energetically optimized in
the oxidized state, respectively in the reduced state, applying the PBE0 density
functional [121] and the def2-TZVP basis set [122] to all atoms as implemented in
NWChem (Version 6.1) [123]. During geometry optimization the positions of the
carbon atoms were kept frozen to their positions in the crystal structure, respectively
to those in the homology model. To account for the antiferromagnetic coupling, the
broken symmetry approach [124, 111] was applied, using the cdft option of NWChem
to enforce the corresponding spin state for the two FeS(SCH2CH3)2 halves of the
iron-sulfur cluster. Subsequently, single point calculations on the obtained geome-
tries were carried out using the larger def2-TZVPP basis set [122] and also applying
following density functionals: BP86 [125, 126], PW91 [126], B3LYP [127, 128], M06
[129], as well as B(5%HF)P86 [130, 131]. Whereas BP86 and PW91 are local func-
tionals, PBE0, B3LYP, M06, and B(5%HF)P86 are non-local hybrid functionals
that involve various amounts of Hartree-Fock exchange. The latter was introduced
by Szilagyi et al. [130, 131] based on superior performance for iron-sulfur clusters.
In contrast to PB86 the exchange part consists of 5% Hartree-Fock and 95% of the
Becke88 functional. Within NWChem the B(5%HF)P86 formalism was specified by
the keyword line “xc becke88 0.95 hfexch 0.05 perdew86 1.0”. Furthermore the key-
word “grid fine” was used to request a higher grid resolution than the default. The
def2-TZVPP basis set likewise showed to be a reasonable trade-off regarding com-
putational demand, particularly in comparison to the 6-311+G(d) basis set [131].
The electronic reorganization energy upon one-electron reduction of the Adx was
obtained as the difference in energy between the oxidized and reduced states of the
two models systems. This energy corresponds to the adiabatic ionization poten-
tial of the iron-sulfur cluster in the reduced state (IPred). The contribution to the
shift of the redox potential in the T49∆ mutant due to the involved structural rear-
rangement of the iron-sulfur cluster can likewise be obtained from the difference of
the adiabatic ionization potentials between wild-type and mutant. Results for the
various density functionals are summarized in table 5.2.
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distance/angle/dihedral angle wild-type T49∆ mutant
Fe1. . . Fe2 2.8856 (2.9503) 2.8075 (2.8494)
Fe1-S1 2.2369 (2.4903) 2.3388 (2.2087)
Fe1-S2 2.2369 (2.3830) 2.2180 (2.3078)
Fe2-S1 2.2251 (2.2078) 2.2291 (2.4709)
Fe2-S2 2.3525 (2.2829) 2.3585 (2.3377)
S1-Fe1-S2 101.8◦ (96.2◦) 104.4◦ (108.7◦)
Fe1-S2-Fe2 77.9◦ (78.4◦) 75.6◦ (75.7◦)
S2-Fe2-S1 102.1◦ (107.7◦) 103.4◦ (99.5◦)
Fe2-S1-Fe1 78.2◦ (77.5◦) 75.8◦ (74.8◦)
Fe1-S1-Fe2-S2 2.1◦ (2.8◦) 6.8◦ (8.9◦)
Table 5.1: Geometric data of the optimized iron-sulfur clustersa
a distances given in Angstrom for the oxidized states. Values for the reduced states are
given in parenthesis.
5.3 Results
5.3.1 Electronic effect of the distorted iron-sulfur cluster
Structural optimization of the Fe2S2(SCH2CH3)4 model compounds showed the
expected increase of the iron-iron distance in the reduced state of 0.065 A˚ for the
wild-type model and of 0.042 A˚ for the T49∆ mutant model. This is similar to
the value used by Mouesca and coworkers (0.04 A˚) for their Fe2S2(SCH3)4 model
compounds based on structural data from synthetic analogs [111]. For the same
molecular system Shoji and coworkers obtained a larger increase of 0.1 A˚ using a
double zeta basis set and the B3LYP density functional [112]. The superposition of
the wild-type and T49∆ mutant iron-sulfur cluster shows that the deletion of Thr49
mostly affects the side chain of Cys46 and in particular of Sγ, which is now in a
different position with respect to the distal iron atom (see figure 5.2). Structural
details of our optimized Fe2S2(SCH2CH3)4 model systems are given in table 5.1.
The calculated adiabatic ionization potentials IPred and therefore also the contribu-
tions to the redox potential of the T49∆ mutant show a strong dependence on the
density functional being used (see table 5.2). The PBE0 formalism seems to overes-
timate the electronic reorganization energy upon one electron reduction. The effect
is, however, less pronounced for single point calculations using the larger TZVPP
basis set. The overestimation is also present in the other non-local density func-
tionals, which involve large amounts of Hartree-Fock exchange: M06 (27%), PBE0
(25%), and B3LYP (20%). These predict contributions of more than -90mV for the
T49∆ mutant. The other used density functionals that either do not make use of
Hartree-Fock exchange (BP86 and PW91), or only to a much smaller extent (5%
in B(5%HF)P86), yield much smaller contributions (around -50mV). Therefore we
attribute the overestimation to the large extent of Hartee-Fock exchange in the non-
local density functionals. This is in line with the finding that the popular B3LYP
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Figure 5.2: Superposition of the wild-type (cyan) and T49∆ mutant (orange) of Adx
focusing on the region around the [2Fe2S] cluster. The deletion of Thr49 mostly affects
the side chain of Cys46, whereby its Sγ atom (pink) coordinates the distal iron atom in
a different angle. The structural changes lead to a substantially lower redox potential of
this mutant
functional is less well suited for the calculation of electronic properties of iron-sulfur
clusters [131]. Using the non-local density functionals, the obtained difference of
the adiabatic ionization potentials between wild-type Adx and the T49∆ mutant
is within 10mV, giving rise to a contribution between -44mV and -54mV to the
experimentally observed -87mV change in redox potential. Thus the conformational
changes in the T49∆ mutant, which predominately affect the side chain of Cys46,
which is part of the coordination sphere of one iron atom, substantially contribute
to the lower redox potential.
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Level of Theory Fe2S2(SCH2CH3)4[WT ]
c Fe2S2(SCH2CH3)4[T49∆]
d
PBE0/def2-TZVP -4.335 eV -4.505 eV (-171 mV)
PBE0/def2-TZVPP -4.387 eV -4.482 eV (-95 mV)
M06/def2-TZVPP -4.520 eV -4.632 eV (-112 mV)
B3LYP/def2-TZVPP -4.333 eV -4.427 eV (-94 mV)
PB86/def2-TZVPP -4.714 eV -4.758 eV (-44 mV)
PW91/def2-TZVPP -4.822 eV -4.872 eV (-50 mV)
B(5%HF)P86/def2-TZVPP -4.619 eV -4.673 eV (-54 mV)
Table 5.2: Calculated adiabatic ionization potentials (IPred) of the iron-sulfur clusters
and corresponding contribution to the shift of the Adx redox potentiala
a The contribution to the shift of the redox potential is given in parenthesis. The experi-
mentally observed shift for the T49∆ mutant is -87 mV.
b Single point calculations on the energetically optimized geometries of the oxidized and
reduced states of the respective model systems at PBE0/def2-TZVP level of theory (please
see computational methods section for details).
c Adx wild-type model.
d Adx T49∆ model.
5.3.2 Effect of mutations in position 108
So far shorter mutants down to position 108 have been made [113]. It was shown
that the proline in this position is important for folding and stabilization of the
protein, because mutants where the residues above position 107 are deleted exhibit
higher sensitive to denaturation by urea [45]. Corresponding mutations create a
cavity in the protein, because van der Waals contacts to neighboring amino acids
(His56, Ile58, and Val107) are lost. Therefore even larger molecules present in the
solvent, such as urea, now have access to the interior. Likewise we observed that
other amino acids in position 108 such as arginine or lysine show only about 10% of
the expression level of other Adx 4-108 mutants that contain the terminal proline.
5.3.3 Rational design of mutants
According to Zhou [56], a strong change of the redox potential would be expected by
replacing a hydrophobic amino acid in the interior of Adx by a polar residue close to
the FeS cluster. Furthermore it is necessary that the resulting dipole vector of the
polar side chain either points towards the FeS cluster (resulting in an increase of the
redox potential) or conversely away (leading to a decrease of the redox potential).
From our structural alignment of Etp1 and Adx we identified Phe43 as promising
position, because it is close to the FeS cluster and also buried within the protein.
Electrostatic shielding is also stronger which should give a big impact on the redox
potential. Furthermore Phe43 is replaced by leucine in Etp1, which indicates some
variability in this position. To experimentally verify this simple model based on the
theories of Born and Kirkwood regarding point charges and dipoles, we proposed
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two amino acids, namely Asparagine and Glutamine, that should have opposite
influences on the redox potentials, since their dipole moments point to different
directions. This postulation was not experimentally evaluated so far.
5.4 Conclusion
In our efforts for designing new mutants of bovine Adx to lower its redox potential
we first exploited why certain mutations have severe effects on the redox potential
and how we could propose new mutants in the future.
Our computed adiabatic ionization potentials of the [2Fe2S] cluster in the geome-
tries adopted in the wild-type and the T49∆ deletion mutant of bovine adrenodoxin
strongly suggest that the experimentally observed difference between the correspond-
ing redox potentials is essentially due to the changes in the geometry around the
iron-sulfur cluster. The arrangement of the ligating cysteines in the protein en-
vironment causes the reduced state to become energetically less destabilized, thus
facilitating electron uptake, which results in lower redox potentials, particularly for
the T49∆ deletion mutant.
In an attempt to introduce new mutations we investigated the approach that was
formulated by Zhou[56]. They used a simplified sphere model for protein and intro-
duced the idea of setting dipole directions of amino acids in relation to the redox
potential. The concept is extremely interesting and wasn’t carried out on Adx so far,
despite many mutations were tested over the years. Especially since an exchange of
amino acid phenylalanine at position 43 wasn’t considered yet. Hence for evaluation
of our postulation an experimentally verification is still due. Building up on this one
could be able to predict results of exchanges of amino acids. Furthermore this could
be extended to other ferre- or flavodoxins affecting other CYP P450 redox systems.
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Chapter 6
Engineering of versatile redox
partner fusion enzymes that
support monooxygenase activity of
functionally diverse cytochrome
P450s
The results and discussion sections (6.1 and 6.2) as well as figures 6.1, 6.2, 6.3, 6.4,
6.5, 6.6, 6.7 and tables 6.1, 6.2, 6.3 were adapted unaltered from our publication
[132], whereas the experimental section is omitted here.
This chapter was published as “Engineering of versatile redox partner fusion
enzymes that support monooxygenase activity of functionally diverse cytochrome
P450s” in collaboration with the labs of Prof. Dr. Vlada Urlacher from Du¨sseldorf
and Prof. Dr. Bernhardt from Saarbru¨cken.
Not only does the dependence on NAD(P)H as an electron donor and redox partners
[11] limit the application of CYPs as biocatalysts but also the identification of
physiological redox partners [11, 133]. Therefore surrogate electron transfer systems
are used to characterize the functional and biocatalytic application of CYPs. In
different approaches the fusion of CYPs with redox partners have been established
to reduce complexity as well as enhance the performance of the CYPs through
faster electron transfer [134, 135, 91, 136, 137, 138, 139].
In this work the flavodoxin YkuN from B. subtilis was fused to the N-terminus
of the flavodoxin reductase Fpr from E. coli. To gain insights to the influence
of the linker region we varied the type as well as the length of it. Tested
were flexible Glycine (GGGGS)n and stiffer Proline linkers ([E/L]PPPP)n of
various lengths (with n = 1 - 5). Subsequently their activity was measured by
determining their ability to support catalysis to a variety of CYPs in vitro. A
proof why certain linkers work better than others was supported by MD simulations.
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6.1 Results
6.1.1 Construction of redox partner fusion enzymes consist-
ing of B. subtilis YkuN and E. coli Fpr
The flavodoxin YkuN from Bacillus subtilis is a promiscuous electron carrier capable
of transferring electrons to a variety of P450s, including endogenous CYP107H1
(P450 BioI) and CYP109B1, but also to heterologous P450s such as CYP154A8
from Nocardia farcinica or CYP154E1 from Thermobifida fusca YX [92, 89, 140].
Herein, YkuN is typically paired with the flavodoxin reductase Fpr from E. coli,
which provides the NADPH-derived electrons. The ”mixed” redox pair Fpr/YkuN
often outperforms physiological redox pairs such as E. coli Fpr/FldA or P. putida
PdR/Pdx [92, 140]. Consistent with this, Fpr/YkuN supported substantially higher
conversion of myristic acid by CYP109B1 than the Fpr/FldA system (Fig. 6.1(a)).
Importantly, even in the case of natural CYP redox chains, such as
PdR:Pdx:P450cam, excess of the ferredoxin Pdx is required for productive CYP
catalysis in vitro [141]. Similarly, for Fpr/YkuN/CYP systems, a respective stoi-
chiometry of 1:10:1 is usually sufficient to efficiently drive CYP catalysis in vitro
[92, 140]. Thus surplus of flavodoxin or ferredoxin overcomes apparent rate-limiting
steps in electron transfer [92, 141, 142]. In support of this, a 1:10:1 Fpr/YkuN/-
CYP109B1 system achieved 36% higher conversion of myristic acid than a 1:1:1
system (fig. 6.1(a)), which is consistent with the function of YkuN as an electron
shuttle that transfers the NADPH-derived electrons from the reductase to the CYP
[89, 142]. A stimulatory effect was also noted for the alternative system using the E.
coli flavodoxin FldA (fig. 6.1(a)). Nevertheless, independent of the stoichiometry
applied the Fpr/YkuN redox pair proved to be superior to Fpr/FldA in supporting
CYP109B1 catalysis, which makes YkuN a promising candidate for covalent fusion
to Fpr. YkuN was fused to the N-terminus of Fpr, leaving the C-terminus of Fpr
free, as it was demonstrated previously that attachment of FldA to the C-terminus
of Fpr leads to reduced enzyme function, whereas constructs with the fusion partners
in reversed order were substantially more active [91]. Attachment of the flavodoxin
to the C-terminus of Fpr likely interferes with the function of the aromatic residues
at the extreme C-terminus of Fpr, which are important for nucleotide binding and
electron exchange [143, 144, 145]. It is worthy of note that homologous catalytic
residues within the reductase domain of natural fusion proteins such as CPR and
self-sufficient CYPs such as CYP102A1 are also found at the C-terminus [12, 146].
To optimize activity of the YkuN-Fpr (YR) fusion construct both flexible (GGGGS)n
and rigid ([E/L]PPPP)n linkers of different lengths (n = 1 - 5) were placed between
the fusion partners. Thus, 11 different fusion constructs were created that were
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Figure 6.1: Myristic acid conversion by B. subtilis CYP109B1 supported by different re-
dox partners. Reactions were started by the addition of a mixture of NADPH and myristic
acid and allowed to proceed for 120 min under the support of an NADPH regenerating
system. (a) CYP109B1 (1 µM) conversion reactions were carried out in the presence of
non-fused redox partners Fpr and FldA (black bars), Fpr and YkuN (white bars) or with
different YkuN-Fpr fusion constructs (grey bars). Reductase (Fpr) and flavodoxin (FldA
or YkuN) together with CYP109B1 were employed at respective ratios of 1:1:1, 1:10:1
and 4:4:1. Reactions conducted with YkuN-Fpr (YR) fusion constructs and CYP109B1
were carried out at a respective ratio of 4:1. YR indicates the linker-less YkuN-Fpr fusion
construct, whereas linker designations P1 - P5 and G1 - G5 correspond to linker sequences
(GGGGS)n and ([E/L]PPPP)n of different lengths (n = 1 - 5). The data presented are
average values of 3 - 6 independent conversion reactions with indicated standard deviation.
(b) Myristic acid conversion by CYP109B1 in the presence of different concentrations of
selected fusion constructs or non-fused Fpr/YkuN. The ratio of non-fused redox partners
was maintained at 1:1 (taken from [132]).
expressed in E. coli. The corresponding fusion proteins were subsequently isolated
from the soluble protein fraction and purified to near homogeneity by IMAC, typ-
ically yielding 1 - 2 mg of purified fusion protein from 40 ml culture (OD600 = 4 -
5).
6.1.2 Ykun-Fpr fusion constructs support monooxygenase
activity of CYP109B1
The ability of the fusion constructs (4 µM) to support CYP monooxygenase activity
was tested in vitro with CYP109B1 (1 µM) using myristic acid as substrate (fig.
6.1(a)). Because the stoichiometry of the fused redox partners is fixed at 1:1, control
reactions were conducted with 4 µM each of non-fused Fpr and YkuN. Independent
of the flavodoxin used (FldA or YkuN), myristic acid conversion achieved with the
4:4:1 reconstituted system was nearly equal to that obtained with the commonly
used 1:10:1 system (fig. 6.1(a)). Thus, in total less redox protein was required to
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obtain a similar level of conversion. Importantly, the different fusion constructs were
all able to support CYP109B1 catalysis (fig. 6.1(a)), which indicates that the co-
valently attached Fpr and YkuN have retained their ability to deliver the necessary
electrons to CYP109B1. The linker-less fusion YR exhibited appreciable activity,
supporting ∼38% conversion of myristic acid (fig. 6.1). Nevertheless, conversion
was substantially lower than with equivalent amounts of non-fused Fpr/YkuN, sug-
gesting reduced activity upon direct attachment of the redox partners. Introduction
of a linker between YkuN and Fpr however substantially improved activity. In par-
ticular the fusion constructs YR-P4 and YR-P5 supported high myristic acid con-
version (79% and 86%, respectively), which is close to the 94% conversion achieved
with non-fused Fpr/YkuN (fig. 6.1(a)). Quantitative product analysis revealed
that both the regioselectivity of CYP109B1 for myristic acid hydroxylation as well
as product distribution was not affected by the fusion constructs.In all cases, the
carbon atoms C-11 (ω3) and C-12 (ω2) of myristic acid were preferentially hydrox-
ylated. Interestingly, the fusion constructs carrying proline-rich linkers (P1 - P5)
in all cases outperformed their glycine-rich (G1 - G5) counterparts (fig. 6.1(a)).
A similar phenomenon has previously been observed upon fusion of E. coli FldA
to Fpr [91]. Moreover, the performance of the P-linker constructs seems to be de-
pendent on the linker length, supporting higher conversion with increased linker
length, whereas for the G-linker constructs a dependence on linker length was not
evident (fig. 6.1(a)). Spectral analysis of the different YkuN-Fpr fusion constructs
revealed nearly identical absorbance characteristics (fig. 6.2), which indicates that
the fusion proteins have a similar co-factor content (Fpr-FAD and YkuN-FMN) as
well as a similar cofactor-protein environment. It seems therefore unlikely that the
differences in activity between the fusion constructs relate to linker induced effects
on cofactor binding or protein folding. The performance of the fusion constructs
was further investigated using different redox protein concentrations (0 - 8 µM). In
all cases, sigmoid curves were obtained over the range of concentrations tested (fig.
6.1(b)). The dependence of CYP109B1 activity on the fusion protein concentra-
tion was clearly different from that of an equivalent system of non-fused Fpr/YkuN
maintained at a 1:1 ratio, and also differed among the fusion constructs, which in-
dicates rather complex behaviour (fig. 6.1(b)). Overall, YR-P5 proved the most
effective fusion construct, as it supported nearly complete conversion of myristic
acid at protein concentrations of 4 - 8 µM, much like the non-fused redox partners.
However, at concentrations <4 µM, the performance of YR-P5 dropped well below
that of the non-fused Fpr/YkuN (fig. 6.1(b)). A reduced performance at low fusion
protein concentration was also observed for the other tested fusion constructs (fig.
6.1(b)). As a measure for the overall performance of the redox partners, the concen-
tration of the redox enzymes at which 50% of myristic acid (EC50) was converted
by CYP109B1 was estimated from fig. 6.1(b). The approximate EC50 are 0.8 µM
for non-fused Fpr/YkuN, 2.7 µM for YR-P5, 3.5 µM for both YR-P1 and YR-G1,
3.6 µM for YR-G5 and 4.5 µM for the linker-less construct YR, which demonstrates
that YR-P5 is the superior fusion construct.
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Figure 6.2: Spectral properties of the individual and fused redox partners, YkuN and
Fpr. Arbitrary amounts of indicated redox protein were diluted in appropriate buffer (A,
50mM KPi pH 7.5, 500 mM NaCl, 20% (v/v) glycerol, and B, 50 mM Tris-HCl pH 7.5),
typically yielding final concentrations in the range of 4 - 8 µM. Spectra were recorded at
25◦C using a thermostated Perkin Elmer Lambda 35 spectrometer. Presented normalised
spectra are the average of 3 recorded spectra that were corrected for buffer absorbance
(taken from [132]).
6.1.3 Intrinsic properties of the (GGGGS)n and
([E/L]PPPP)n linkers
To further evaluate the properties of the (GGGGS)n and ([E/L]PPPP)n linkers
molecular dynamics (MD) simulations were carried out. MD simulations of the
G-linkers revealed that starting from a linear extended conformation these linkers
readily fold into more compact random structures (fig. 6.3(a)). Collapse of the
extended conformation is particularly evident for linkers G3, G4 and G5, which
consist of 3, 4 and 5 (GGGGS)-repeats, respectively. These linkers exhibited a
substantial (>1 A˚) decrease in the radius of gyration (Rg) over time (fig. 6.3(b)).
Moreover, the Rg of the G4 and G5 linker exhibited large oscillations over time,
which indicates substantial structural rearrangements and high structural flexibility.
Structural behaviour of the ([E/L]PPPP)n linkers on the other hand was clearly
different. The Rg of the different P-linkers remained largely constant over time,
with only minor oscillations observed for linkers P3 - P5 (fig. 6.3(c)). Thus, the
P-linkers effectively maintained their linear conformation. Consequently, the Rg
of the P-linkers exhibited a dependence on the linker length. For each additional
([E/L]PPPP)-segment the Rg increased by ∼0.4 - 0.5 A˚ (fig. 6.3(c)). Linker P5,
which consists of 25 residues forms an exception to this as it exhibited an Rg similar
to that of the P4 linker, i.e. ∼1.8 A˚ (fig. 6.3(c)). Overall bending of the long
P-linkers may have contributed to this occurrence (fig. 6.3(a)).
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6.1.4 Influence of auxiliary YkuN on CYP109B1 catalysis
driven by the YkuN-Fpr fusion constructs
In comparison to the separate redox enzymes the fusion constructs exhibit a reduced
performance at low protein concentration (fig. 6.1(b)), which may indicate that one
(or both) of the fused redox partners is limiting the P450-catalysed reaction. With
reconstituted P450 systems the electron shuttle ferredoxin/flavodoxin is usually a
major limiting factor that is typically overcome by applying an excess of this electron
transfer protein [92, 141, 142]. To investigate this, the different fusion constructs
(1µM) were incubated together with CYP109B1 (1µM) in the absence or presence
of an excess of YkuN (4 or 9µM). In all cases, mixing the fusion proteins with
additional YkuN led to an increase in myristic acid conversion (fig. 6.4), which
confirms that YkuN is limiting the reaction. By increasing the concentration of the
fusion constructs itself in the P450-catalysed reaction, this apparent limitation was
also (partly) overcome (fig. 6.1(b)).
Since the reductase (Fpr) domain of the fusion constructs is capable of donating
electrons to the auxiliary electron shuttle YkuN, this also indicates that no strict
functional coupling between the Fpr and YkuN domain exists within the fusion
constructs. Generally, electron transfer rates are thought to be controlled in part
by the distance between the redox centres [147]. Considering the YkuN-Fpr fusion
constructs it is likely that both the length and the structural properties of the linker
contribute to the relative distance between the respective redox centres. Regarding
the rigid nature of the ([E/L]PPPP)n linkers (fig. 6.3) it seems plausible that in
particular long P-linkers might facilitate a higher degree of separation of the fusion
partners. In line with this, the increase in conversion upon YkuN addition was
much more pronounced for fusion constructs carrying the rigid P-linkers (fig. 6.4),
which more effectively maintain an extended conformation than their glycine-rich
counterparts (fig. 6.3). In fact, the highest increase in myristic acid conversion
governed by the addition of YkuN was observed for the YR-P5 construct which
carries the longest P-linker tested (25 residues), achieving a similar conversion as
the comparable 1:10 system of non-fused Fpr/YkuN (fig. 6.4).
6.1.5 NADPH oxidation rates and coupling efficiencies mea-
sured with the YkuN-Fpr fusion enzymes
The overall performance of a reconstituted P450-redox partner system depends
amongst others on its NAD(P)H oxidation rate and the coupling efficiency between
NAD(P)H oxidation and P450 substrate conversion. Since delivery of electrons to
CYP109B1 depends on functional reductase (Fpr) as well as flavodoxin (YkuN), a
loss of electrons may occur either upon electron transfer from Fpr to YkuN or from
YkuN to CYP109B1, which in both cases will lead to uncoupling between NADPH
oxidation and product formation.
6.1. RESULTS 67
The NADPH oxidation rate and the coupling efficiency were determined for various
reconstituted systems (Table 6.1). CYP109B1 reconstituted with the non-fused
redox partners exhibited the highest NADPH oxidation rate, i.e. 26 nmol(nmol ×
P450)−1min−1, along with a coupling efficiency of 28.3%. In contrast, for the fusion
constructs substantially lower NADPH consumption rates were observed, whereas
the coupling efficiency was markedly improved (table 6.1). Direct attachment of
YkuN to Fpr (YR) led to a ∼1.8-fold improvement of the coupling efficiency (49.8%)
and a more than 8-fold decrease in NADPH oxidation rate (table 6.1). In comparison
to YR, the superior construct YR-P5 (fig. 6.1) showed a similar coupling (48.9%),
whereas the NADPH oxidation rate was 3.6-fold higher, i.e. 11.3 nmol(nmol ×
P450)−1min−1 (table 6.1). The highest coupling efficiency of 81.2% was however
observed for YR-G5, which, notably, exhibited the lowest NADPH oxidation rate of
1.4 nmol(nmol × P450)−1min−1.
Reconstituted system a NADPH oxidation rate b Coupling efficiency (%)
Fpr / YkuN / CYP109B1 - [4:4:1] 26.0 ± 1.9 28.3 ± 3.6
YR / CYP109B1 - [4:1] 3.1 ± 0.3 49.8 ± 8.3
YR-P1 / CYP109B1 - [4:1] 12.7 ± 1.3 62.1 ± 5.1
YR-P5 / CYP109B1 - [4:1] 11.3 ± 1.9 48.9 ± 3.4
YR-G1 / CYP109B1 - [4:1] 6.6 ± 0.3 72.4 ± 3.6
YR-G5 / CYP109B1 - [4:1] 1.4 ± 0.2 81.2 ± 4.1
Table 6.1: NADPH oxidation rate and coupling efficiency of the CYP109B1-catalysed
conversion of myristic acid, supported by different redox partners. Presented data repre-
sent average values of at least three independent myristic acid conversion reactions.
a Values in brackets indicate applied ratio as well as final concentration (µM) of indicated
proteins.
b Rates are given in nmol NADPH per nmol CYP109B1 per minute. The background
NADPH consumption rate in the absence of redox partner(s) was 0.1 ± 0.0 (taken from
[132]).
6.1.6 Reduction of CYP109B1 Fe3+-heme by the YkuN-Fpr
fusion constructs
Since the YkuN-Fpr fusion constructs exhibited attenuated NADPH oxidation rates
along with improved coupling, the question arises whether the crucial step of electron
transfer to the P450 is also influenced upon attachment of YkuN to Fpr. The
reduction of the Fe3+ to Fe2+-heme can be conveniently monitored by the addition
of carbon monoxide (CO), yielding a stable complex that exhibits the characteristic
absorbance maximum at 450 nm [148]. Indeed, absorbance spectroscopy of the
anaerobic reduction of CYP109B1 in the presence of CO by the different redox
partners revealed the formation of the typical absorbance peak at ∼450 nm, which is
governed by the reduction of Fe3+ to Fe2+-heme and the subsequent formation of the
stable heme-Fe2+-CO complex. Typical traces for the time dependent reduction are
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shown in fig. 6.5. CYP reduction occurred rather slowly under the tested conditions
(fig. 6.5). Data were fit to a bi-exponential function, revealing a slow and a fast
phase; the corresponding reduction rates are shown in table 6.2. Reduction occurred
Reconstituted system a Heme-iron reduction rate b
k1(s
−1) k2(s−1)
Fpr / FldA / CYP109B1 - [4:4:1] 0.004 ± 0.001 0.027 ± 0.008
Fpr / YkuN / CYP109B1 - [4:4:1] 0.009 ± 0.001 0.078 ± 0.023
YR / CYP109B1 - [4:1] 0.002 ± 0.001 0.030 ± 0.002
YR-P5 / CYP109B1 - [4:1] 0.008 ± 0.002 0.045 ± 0.005
YR-G5 / CYP109B1 - [4:1] 0.007 ± 0.001 0.035 ± 0.002
Table 6.2: Reduction of B. subtilis CYP109B1 Fe3+-heme by different redox partners.
a Values in brackets indicate applied ratio as well as final concentration (µM) of the pro-
teins in the employed reconstituted systems.
b The heme-iron reduction rates were measured as described in the Methods section. Ki-
netic traces were fit to a bi-exponential function, revealing a slow and a fast phase. Typical
kinetic traces and corresponding fits are shown in the online Supplemental Information.
Presented reduction rates represent average values of at least three independent reactions
carried out under anaerobic conditions at 20◦C (taken from [132]).
fastest by the non-fused Fpr/YkuN, exhibiting a k1 of 0.009 s−1 and k2 of 0.078 s−1.
For the linker-less fusion YR corresponding rates were 4.5 and 2.6-fold decreased,
respectively. In contrast, for the fusion constructs carrying the long P5 or G5 linker,
k1was nearly identical to that of the non-fused Fpr/YkuN and k2 was decreased to
a lesser extent (table 6.2). Of the tested fusion constructs, the superior YR-P5 also
exhibited the highest heme-iron reduction rate (k1 = 0.008 s−1 and k2 = 0.045 s−1
). Thus, introduction of the P5 linker (25 residues) between YkuN and Fpr led to a
substantial increase of the heme-iron reduction rate.
6.1.7 Versatility of the YkuN-Fpr redox fusion enzymes
From a biotechnological point of view, a redox partner system desirably should have
the ability to transfer electrons to different terminal acceptors. To demonstrate
cross-reactivity, selected fusion constructs were additionally tested with CYP154E1
from Thermobifida fusca YX, CYP106A2 from Bacillus megaterium ATCC 13368
and bovine CYP21A2. CYP154E1 is a versatile monooxygenase that converts a
large variety of substrates, including fatty acids and alcohols, as well as acyclic and
bulky cyclic terpenoids [140, 149, 150]. Since Fpr/YkuN are known to effectively
support CYP154E1 catalysis [140, 149, 150] it is expected that the YkuN-Fpr fu-
sion constructs are also able to act as surrogate redox partners. To investigate
this, selected fusion constructs were tested for their ability to support CYP154E1
catalysis using β-ionone as substrate (fig. 6.6). Ionones are cyclic terpenoids that
are key fragrance components used for the production of perfumes, cosmetics and
other fine chemicals [151]. Moreover, β-ionone is an important intermediate in the
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manufacturing of vitamin A, while its oxygenated derivative 4-hydroxy-β-ionone is
a key intermediate in the synthesis of carotenoids and the plant hormone abscisic
acid [152, 153, 154].
Non-fused Fpr/YkuN (1:10 or 4:4 system) effectively supported CYP154E1 catalysis,
achieving >70% conversion of β-ionone in 1 h (fig. 6.6). Thus, in addition to
the previously reported terpenoid substrates [150], β-ionone is also converted by
CYP154E1. As expected, the fusion constructs were able to support CYP154E1
catalysis, of which YR-P5 again proved most effective at driving CYP catalysis (fig.
6.6). In the presence of YR-P5 ∼1 mM of β-ionone was converted in 1 h, yielding
a turnover of ∼16 min−1, while non-fused Fpr/YkuN (4:4) supported a turnover
of ∼24 min−1. The YR-P5/CYP154E1 (4:1) system achieved a coupling efficiency
of ∼50%, whereas with the non-fused enzymes ∼44% was measured. Furthermore,
under cofactor regeneration conditions, total turnover numbers (TTN) were 1582
with YR-P5 and 1948 with the non-fused Fpr/YkuN. Regardless whether Fpr and
YkuN were fused or not, in all cases a major oxidation product was formed, which
was identified as 4-hydroxy-β-ionone by comparison to MS analysis of an authentic
reference substance [155].
To further substantiate functional promiscuity, the best construct YR-P5 was tested
with CYP106A2 and CYP21A2 using progesterone as substrate in both cases. It is of
note that these CYPs have not been tested previously with Fpr/YkuN as surrogate
redox partners. CYP106A2 is a regio- and stereoselective 15β-hydroxylase of 3-oxo-
∆4-steroids [19, 97] that recently has been demonstrated to also accept 3-hydroxy-
∆5-steroids as well as di- and triterpenes as substrates [156, 28]. Herein, the bovine
adrenodoxin reductase (AdR) and adrenodoxin (Adx) typically serve as surrogate
redox partners. Interestingly Fpr/YkuN and its fused derivative YR-P5 were able
to functionally substitute for AdR/Adx in the CYP106A2-mediated conversion of
progesterone (table 6.3). Moreover, performance of the 4:4:1 Fpr/YkuN/CYP106A2
system was virtually identical to that of the 4:4:1 AdR/Adx/CYP106A2 system,
both with respect to progesterone conversion and product distribution (table 6.3).
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Figure 6.3: MD simulations of the (GGGGS)n and ([E/L]PPPP)n linkers used to
functionally connect YkuN and Fpr. (a) Structural snapshots of (GGGGS)n and
([E/L]PPPP)n linkers of length 1 and 5. Depicted in each panel are the starting con-
formations (left) and the lowest energy conformation found during the 20 ns MD simu-
lations (right). Development of the radius of gyration (Rg) during MD simulations for
(GGGGS)n and ([E/L]PPPP)n linkers of lengths (n = 1 - 5) are shown in (b) and (c),
respectively. The strong decrease in Rg for (GGGGS)n linkers reflects the hydrophobic
collapse, whereas the ([E/L]PPPP)n linkers remain in an extended conformation (taken
from [132]).
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Figure 6.4: Influence of auxiliary YkuN on CYP109B1 catalysis driven by the different
YkuN-Fpr fusion constructs. Myristic acid conversion with CYP109B1 (1 µM) was carried
out in the presence of the different Ykun-Fpr fusion constructs either in the absence (-
YkuN) or presence of additional YkuN (4 or 9 µM). In all cases reactions were started by
the addition of a mixture of NADPH and myristic acid and allowed to proceed for 120 min
under the support of an NADPH regenerating system. The Fpr/YkuN/CYP109B1 system
reconstituted at 1:10:1 and 1:1:1 ratio, respectively achieved 96% and 60% conversion of
myristic acid in 120 min (taken from [132]).
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Figure 6.5: CYP109B1 heme iron reduction by different redox partners (taken from
[132]).
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Figure 6.6: Conversion of β-ionone by T. fusca YX CYP154E1 supported by selected fu-
sion constructs. Conversion reactions were carried out in the presence of 1 µM CYP154E1
and 4 µM of indicated fusion constructs. Control reactions with non-fused Fpr/YkuN were
conducted with 1 µM CYP154E1 together with either 1 µM Fpr + 10 µM YkuN [1:10],
or 4 µM Fpr + 4 µM YkuN [4:4]. In all cases the initial concentration of the substrate
β-ionone was 2 mM. Reactions were started by the addition of NADP+ under support of
an NADPH regenerating system and stopped after 1 h (taken from [132]).
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Redox partners Ratio a Conversion time (min) Progesterone conversion(%) Compounds(%)
Prog b 15 βOH b mono-OH b poly-OH b
AdR/Adx
(4:4:1)
30 96.0 ± 0.5 4.0 ± 0.5 81.7 ± 1.0 8.7 ± 1.3 5.6 ± 0.9
120 99.0 ± 0.1 1.0 ± 0.1 81.1 ± 0.5 6.9 ± 0.5 11.0 ± 0.7
(10:10:1)
30 96.0 ± 0.6 4.0 ± 0.6 81.5 ± 0.5 7.9 ± 0.1 6.6 ± 0.2
120 96.7 ± 1.0 3.3 ± 1.0 82.6 ± 1.6 7.9 ± 0.3 6.1 ± 1.4
Fpr/YkuN
(4:4:1)
30 92.7 ± 0.7 7.3 ± 0.7 80.4 ± 0.5 4.0 ± 0.4 8.3 ± 0.1
120 98.9 ± 0.0 1.1 ± 0.0 81.9 ± 0.0 4.3 ± 0.0 12.8 ± 0.0
(10:10:1)
5(500µM)c 84.7 ± 5.4 15.3 ± 5.4 80.4 ± 3.1 2.0 ± 0.2 2.2 ± 2.2
30 91.5 ± 1.3 8.5 ± 1.3 63.0 ± 1.0 4.4 ± 0.1 24.1 ± 0.2
60 94.0 ± 0.1 6.0 ± 0.1 58.4 ± 0.7 5.2 ± 0.7 30.5 ± 0.1
90 98.5 ± 0.4 1.5 ± 0.4 68.2 ± 4.2 6.5 ± 0.4 23.8 ± 4.7
120 97.8 ± 0.2 2.1 ± 0.2 66.3 ± 2.6 6.4 ± 0.4 25.2 ± 3.0
YR-P5
(4:1)
30 19.5 ± 2.6 80.5 ± 2.6 19.1 ± 2.1 0.4 ± 0.5 -
60 29.6 ± 5.4 70.4 ± 5.4 29.2 ± 4.9 0.4 ± 0.6 -
90 39.7 ± 16.2 60.3 ± 16.2 39.7 ± 16.2 - -
120 45.9 ± 15.2 54.1 ± 15.2 44.0 ± 13.4 1.9 ± 1.9 -
(10:1)
5(500µM)c 29.7 ± 0.6 70.3 ± 0.6 29.7 ± 0.6 - -
30 75.9 ± 3.8 24.1 ± 3.8 71.3 ± 4.2 3.4 ± 0.5 1.2 ± 0.9
60 80.0 ± 0.9 20.0 ± 0.9 74.9 ± 1.4 3.2 ± 0.8 1.8 ± 0.3
90 90.7 ± 5.3 9.3 ± 5.3 81.5 ± 3.7 3.6 ± 0.8 5.6 ± 1.0
120 94.9 ± 0.7 5.1 ± 0.7 84.9 ± 0.7 4.0 ± 1.3 6.1 ± 0.2
Table 6.3: Product distribution for the CYP106A2-catalysed conversion of progesterone supported by different redox partners. Data
represent average values of three independent conversion reactions with indicated standard deviation.
a Redox partner-CYP106A2 ratio of reconstituted system.
b B. megaterium CYP106A2 hydroxylates progesterone at positions 15β, 6β, 11α and 9α [82]; mono-OH, monohydroxylated proges-
terone at positions other than 15β; poly-OH, di- or polyhydroxylated progesterone.
c To assess turnover, conversion reactions were carried out for only 5 min in the presence of 500 µM progesterone (taken from [132]).
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With both systems nearly all progesterone was converted after 120 min and 15β-
hydroxyprogesterone was the main product formed (table 6.3). The fusion construct
YR-P5 also supported CYP106A2 catalysis, albeit with lower efficacy (table 6.3).
The YR-P5/CYP106A2 (4:1) system achieved ∼46% conversion after 120 min, pro-
ducing almost exclusively 15β-OH-progesterone (table 6.3). By increasing the YR-
P5 concentration (10:1 system) conversion could be enhanced to near completion
(95%) after 120 min, while only minor amounts of undesired polyhydroxylated pro-
gesterone were formed (up to 6%). To assess turnover rates, reactions were carried
out under conditions in which essentially no overoxidation products were formed (5
min reactions using 500 µM progesterone). With the Fpr/YkuN/CYP106A2 system
(10:10:1) nearly 85% of the progesterone was converted, thus achieving a turnover of
169 min−1, whereas with the YR-P5/CYP106A2 system (10:1) nearly 30% proges-
terone conversion was achieved, thus yielding a turnover of 59.4 min−1. To further
illustrate versatility of YR-P5, bovine CYP21A2, which is a membrane-bound mi-
crosomal P450, was used as terminal electron acceptor. CYP21A2 is involved in
the biosynthesis of steroid hormones, and typically catalyses the hydroxylation of
the carbon atom 21 in steroids [157]. In general, CYP21A2 obtains the necessary
electrons from NADPH via an FAD and FMN-containing microsomal CPR [12].
However, it is also able to use AdR and Adx as redox partners [158]. Notably,
YR-P5 supported CYP21A2 catalysis; with YR-P5 40% of the (200 µM) proges-
terone was converted to 21-hydroxyprogesterone in 30 min, while ∼80% conversion
was achieved with non-fused Fpr/YkuN (Fig. 6.7). Taken together, the Fpr/YkuN
redox pair and its fused derivative YR-P5 are able to support the activity of the
steroidogenic CYP106A2 and CYP21A2 in vitro, which indicates that these bacte-
rial electron transfer systems may serve as alternatives to the mammalian electron
transfer systems AdR/Adx and CPR.
6.2 Discussion
Flavodoxins are promiscuous electron carriers that donate electrons to structurally
and functionally diverse enzymes, including pyruvate-formate lyase [159], ribonu-
cleotide reductase [160], key enzymes in photosynthesis [161], nitrogen fixation [162],
methionine [163] and biotin [164] synthesis, but also P450s [92, 89, 142, 165, 166].
The mixed redox pair Fpr/YkuN outperformed the physiological redox pair
Fpr/FldA from E. coli in supporting CYP109B1 catalysis (fig. 6.1(a)), which sug-
gests that electron transfer by the flavodoxin YkuN is more effective. Since YkuN
and CYP109B1 both originate from B. subtilis it is possible that YkuN is the physi-
ological redox partner of CYP109B1 and therefore a more favourable electron carrier
than the heterologous FldA.
Typically, the midpoint potentials of the oxidised/semiquinone (E1’) and
semiquinone/hydroquinone (E2’) couples reported for the short-chain flavodoxin
YkuN are higher than those for the long-chain flavodoxin FldA, i.e. -105 mV and
76 CHAPTER 6. ENGINEERING OF VERSATILE REDOX PARTNERS
Figure 6.7: Conversion of progesterone by bovine CYP21A2 supported by Fpr/YkuN
and their fused derivative, YR-P5. In all cases conversion reactions were carried out in
the presence of 0.5 µM CYP21A2, 200 µM progesterone and 5 µM of indicated redox
partner(s). Corresponding ratios of redox partner(s) relative to CYP21A2 are indicated
in brackets. Reactions were started by the addition of NADPH and supported by an
NADPH regenerating system. Reactions were stopped after 30 min (taken from [132]).
-382 mV [89] vs. -254 mV and -433 mV, respectively [166]. E1’ and E2’ of the
employed E. coli reductase Fpr are -308 mV and -268 mV, respectively [166]. In-
deed, the anaerobic reduction of CYP109B1 heme-iron by YkuN occured 2-3 times
faster than by FldA (table 6.2). Similarly, stopped-flow experiments monitoring the
reduction of B. subtilis CYP107H1 have indicated that YkuN is more effective than
FldA in first electron transfer to palmitoleate-bound CYP107H1, as evidenced by a
∼12-fold higher kred (2.38 s−1 vs. 0.19 s−1) [89]. Thus, accelerated electron transfer
likely contributed to the overall better performance of YkuN compared to FldA in
the CYP109B1-catalysed conversion of myristic acid (table 6.2, fig. 6.1(a)).
The inherent dependence of P450s on electron transfer proteins presents a challeng-
ing limitation in their biotechnological exploitation. To simplify redox chains and to
improve the catalytic properties of P450 systems, a variety of man-made P450 fu-
sion enzymes have been successfully created using a variety of molecular approaches,
including ”Molecular Lego”[136], ”LICRED”[167], and ”PUPPET”[168]. Here, the
versatility and superior properties of YkuN were exploited to generate redox fusion
6.2. DISCUSSION 77
enzymes capable of driving catalysis of different CYPs, using the previously estab-
lished DuaLinX procedure [91] for linker engineering. The catalytic performance of a
reconstituted P450 system is often limited by a low coupling efficiency. Uncoupling
events waste expensive reduced cofactors (NAD(P)H) and lead to the generation
of reactive oxygen species that can cause enzyme inactivation [169]. With non-
physiological redox chains the coupling efficiency is often particularly poor (less than
20%) [92] and also when P450s catalyse reactions with non-physiological substrates,
coupling efficiencies are frequently severely diminished (<10%)[169]. Achieving a
high coupling efficiency is thus a particularly challenging task.
Direct attachment of YkuN to Fpr via genetic fusion led to a 1.8-fold improvement
of the coupling efficiency in CYP109B1-catalysed reactions (table 6.1). Coupling ef-
ficiency could be even further improved by insertion of an appropriate linker between
the fusion partners. In case of the YR-G5 construct a coupling efficiency as high as
81.2% was achieved. Notably, in all cases the CYP109B1 systems reconstituted with
the different YkuN-Fpr fusion constructs exhibited a higher coupling efficiency than
those reported previously using a variety of different redox partners (1.8-45.8%) [92],
which is an advantage under cofactor regeneration condition. However, the NADPH
oxidation rate was markedly reduced.
Despite improved coupling, overall performance of the parental linker-less YkuN-Fpr
fusion construct in P450-catalysed reactions was rather modest in comparison to the
non-fused enzymes (figs. 6.1 and 6.6). A >8-fold reduction in NADPH oxidation
rate (table 6.1) combined with slower electron transfer to the CYP109B1 (table 6.2)
likely contributed to the reduced performance of the YR fusion construct. Insertion
of a suitable linker between the fusion partners however, substantially improved the
overall performance. Herein, long ([E/L]PPPP)n linkers (n = 4 - 5) were particularly
effective (figs. 6.1 and 6.6), which is consistent with previous findings for fusions
between E. coli FldA and Fpr [91]. At protein concentrations ≤4 µM, the superior
construct YR-P5 acted as a nearly equivalent substitute for non-fused Fpr/YkuN in
driving CYP109B1 catalysis (fig. 6.1). Insertion of the P5 linker between the fused
YkuN and Fpr resulted in a 1.5-fold increase in heme iron reduction rate (table
6.2, k2) along with a 3.6-fold higher NADPH oxidation rate, while maintaining a
high coupling efficiency of nearly 50% (table 6.1), thus contributing to the improved
overall performance (fig. 6.1). However, despite poorer coupling efficiency, the non-
fused redox partners proved generally more effective than YR-P5 in supporting P450
catalysis (table 6.3, figs. 6.1, 6.6 and 6.7), which is likely governed by faster overall
electron transfer (accelerated NADPH oxidation as well as P450 reduction). The
higher amount of progesterone overoxidation products formed by CYP106A2 when
the non-fused redox partners are used as opposed to YR-P5, is also consistent with
this notion (table 6.3).
Examination of the linker properties using MD simulations revealed that the
(GGGGS)n linkers are highly flexible and tend to adopt compact random struc-
tures, whereas the ([E/L]PPPP)n linkers maintain their linear conformation and are
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therefore structurally more rigid (Fig. 6.4). These results are consistent with the
notion that glycine-rich and proline-rich amino acid sequences are flexible and rigid
in nature, respectively [170, 171, 172]. Moreover, the high mobility of glycine-rich
linkers is apparent from their lack of structural resolution in X-ray structures of
a multitude of artificial fusion proteins [173]. Due to their flexibility, glycine-rich
linkers are unstructured and tend to provide limited domain separation [174, 175],
whereas structurally rigid linkers, such as proline-rich linkers are more likely to
separate the fusion partners [171, 176].
For flavodoxins the binding areas for the electron donating reductase and the termi-
nal electron acceptor (P450) are partially overlapping, which precludes the formation
of a ternary protein complex [177, 178]. Considering the fusion constructs, an opti-
mal linker should therefore facilitate the formation of an electron transfer complex
between Fpr and YkuN as well as between YkuN and the P450. In view of the
superior performance of the YR-P5 construct these criteria are apparently best met
by the ([E/L]PPPP)5 linker. Indeed, both the activity of Fpr (NADPH oxidation
rate) and YkuN (heme-iron reduction) are reasonably well preserved in the YR-P5
construct (tables 6.1 and 6.2). Herein, the rigid P5 linker may restrict the degrees
of freedom of the fused redox partners, while allowing them to mutually interact
in an effective manner, thus promoting intramolecular electron transfer. On the
other hand, the extended rigid P5 linker (25 residues) may increase the distance
between the redox centres of the fusion partners, thereby disfavouring intramolec-
ular electron transfer and facilitating electron transfer between fusion proteins (i.e.
intermolecularly). The available experimental data for YR-P5 seems to be more
consistent with a predominantly intermolecular electron transfer pathway. YR-P5
lacks a strict functional coupling between the Fpr and YkuN domain and its Fpr
domain is readily accessible for external YkuN (fig. 6.4), which is likely facilitated
by a higher degree of separation of the fusion partners in case of the P5 linker.
Moreover, P450 mediated catalysis exhibited a higher order (sigmoidal) dependence
on fusion enzyme concentration suggesting an intermolecular contribution, whereas
a linear dependence would have been indicative of exclusive intramolecular electron
transfer (fig. 6.1(b)). At elevated redox partner concentration, which increases the
collision frequency between fusion proteins, apparent limitations in electron transfer
were (partially) overcome and the performance of YR-P5 was similar to that of the
non-fused Fpr/YkuN (fig. 6.1(b)).
Finally, the superior construct YR-P5 exhibits versatility as it effectively sup-
ported monooxygenase activity of functionally diverse P450s, including B. subtilis
CYP109B1 (fig. 6.1), T. fusca YX CYP154E1 (fig. 6.6), B. megaterium CYP106A2
(table 6.3) and bovine CYP21A2 (fig. 6.7). Thus, functional promiscuity of YR-P5
is not limited to bacterial P450s.
Considering the feasibility of the Fpr/YkuN system and its fused derivative YR-
P5 for applied biocatalysis, the TTN presented here are rather modest. In case
of CYP154E1 with β-ionone as substrate TTN were 1,582 with YR-P5 and 1,948
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with the non-fused Fpr/YkuN. On the other hand, we recently observed that a
Fpr/YkuN/CYP154E1 system can achieve TTN of up to 20,000 with stilbene as
substrate [179]. Although TTN in P450-based multi-component systems depend
on many factors, the P450-substrate match seems to play a prominent role. For
example, CYP154C5 catalysis supported by PdR/Pdx achieved TTN of 2,440 with
progesterone and 3,341 with androstenedione under optimized conditions [180]. For
the natural fusion P450 BM3 from Bacillus megaterium (and mutants thereof), TTN
values range from 890 with omeprazole [181], 2,200 with n-octane [182], to 6,195 with
anisole [183], and even TTN as high as 24,363 or 45,000 have been reported in case
of cyclooctane [184] and propane [185], respectively.
Taken together, the intrinsic dependence on redox partner(s) represents an impor-
tant limiting factor in the utilization of P450s as biocatalysts. Availability of suitable
redox partner(s) is therefore a prerequisite to successfully explore the catalytic po-
tential of P450s [186]. By covalent fusion the complexity of the bacterial Fpr/YkuN
electron transfer chain was effectively reduced, allowing easy protein production, pu-
rification and handling. Moreover, a stabilising effect on Fpr was noted upon fusion
to YkuN. Through linker engineering the activity of the fusion construct could be
tuned such that the high activity of the individual redox partners and the promis-
cuity for different P450s was largely preserved, with overall best performance of the
YR-P5 construct. The versatile YR-P5 may serve as an effective surrogate electron
transfer system for exploitation of the catalytic potential of (orphan) P450s.
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Chapter 7
Conclusion
During my work I contributed ideas and theoretical calculations that provide ground
for further studies in the biotechnological application of redox systems depending on
adrenodoxin and Electron transfer protein 1, CYP106A2 together with adrenodoxin
reductase.
In a first collaboration with Prof. Bernhardts lab we took part in engineering
CYP106A2 towards a 9-α- and 6-β-hydroxylation. Our suggestions for CYP106A2
mutations towards 6-β-hydroxylations were exchanges at positions 247 (change from
threonine to alanine), 243 (alanine to serine) and 173 (phenylalanine to alanine).
Combining those replacements lead to seven new proteins. The exchange of alanine
to serine at position 243 increased the production of 6-β-hydroxylation of proges-
terone by more than ten-fold which was due to an additional hydrogen-bond to the
carbonyl oxygen in position 21 that could be formed by the substrate progesterone.
Subsequent MD simulations could explain this observation. The distances to the 6-β
position to the central heme iron were shorter than those to the 15-β throughout
the simulation.
In another collaboration we were looking for an optimal fitting redox system for
CYP106A2. Here the combination of ferredoxins Adx, Etp1fd, Fdx2, FldA and
YkuN with reductases Arh1, BmCPR and Fpr resulting in 11 different complexes
was established (chapter 3). Again progesterone was used since it is a well studied
substrate of CYP106A2. The preferred redox system is Adx together with AdR.
The inspected redox systems all were able to deliver electrons from NAD(P)H to
CYP106A2, which was determined experimentally in Prof. Bernhardts lab. The
differences appeared in variable overall turnover of progesterone (e.g. Etp1(516-
618)/AdR had 100% turnover, Etp1(516-618)/BmCPR had 79%) as well as in
product variability including mono- and polyhydroxylated progesterone. When us-
ing Adx(4-108) together with AdR after 30 minutes of conversion, 65% of proges-
terone is polyhydroxylated, 27% is 15β-OH, 5% are other monohydroxylated prod-
ucts and the remaining part is unhydroxylated substrate. Exchanging Adx(4-108)
with Etp1(516-618) shifted the outcome to 18% poly-OH, 78% 15β-OH, 3% other
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monohydroxylated progesterones, and no remaining substrate. Similar results were
seen when investigating Adx(1-128) and AdR or Fdx2 together with Arh1. From
these redox systems, Etp1 and Adx were investigated using theoretical approaches.
Protein-protein docking of Etp1(516-618) and Adx(4-108) to the binding interface of
CYP106A2 revealed the possible reason for this product spectrum. Phe592 (which is
at the corresponding position of Tyr82 in Adx) of Etp1(516-618) binds to Phe107,
Pro359, and Leu356 of CYP106A2 in a sandwich like manner. This allows the
iron-sulfur cluster to approach the heme center of CYP106A2 as close as 19 A˚ in
its closest conformation found. Subsequent electron transfer should therefore be
faster as for Adx(4-108). Here the distance of iron-sulfur cluster and heme center
is 24 A˚. Also position Tyr82 of Adx(4-108) cannot interact with Phe107, Pro359,
and Leu356 of the CYP1062 because it is sterically hindered by Arg14 and Asp41.
But due to larger electrostatic contributions a slower release of Adx(4-108) is con-
ceivable. Those findings suggest that Adx has a slower electron transfer rate than
Etp(516-618) and its interactions are stronger so that the substrate dwells longer in
the active site of the CYP106A2 ending in more polyhydroxylated products.
In chapter 6 the focus lied on the establishment of fused redox systems deliver-
ing electrons to different CYP P450s, B. subtilis CYP109B1, Thermobifida fusca
CYP154E1, Bacillus megaterium CYP106A2 and bovine microsomal CYP21A2, re-
spectively. The redox systems consisted of E. coli ’s Flavodoxin reductase Fpr and
Flavodoxin YkuN of B. subtilis (complex to be named YR). They have been fused
together with flexible glycine (GGGGS)n and stiffer proline linkers ([E/L]PPPP)n
of different lengths (with n = 1 - 5) in Prof. Urlachers lab. Fusing the electron
transfer proteins should lower the complexity of the redox chain as well as improve
the catalytic properties. The best result was seen for the YR-P5 (proline linker
with length of n = 5). Here a 1.7 fold increase of coupling efficiency could be seen
compared to the separated proteins (49% vs. 28%). Nevertheless the oxidation rate
of NADPH as well as the CYP reduction rate decreased by 2.3 and 1.7, respectively.
Theoretical investigation of the linker constructs through MD simulation did pro-
vide proof why in general the proline-rich linkers outperform the glycine-rich ones.
We reconstructed each linker in an elongated conformation with the Hyperchem
program and performed MD simulations for 1 ns with prior energy minimizations
as well as equilibration. We were able to show that the glycine-rich linkers experi-
enced a hydrophobic collapse after a short period of time. The proline-rich linker
stayed stable throughout the simulation and showed only slight bending. The space
provided by the proline-rich linkers allowed the required accessibility of the actual
redox centers, which obviously limits the local turn-over.
Chapter 5 formulates our attempts to systematically investigate amino acid ex-
changes or deletions in bovine Adx regarding the change of its redox potential.
First we analysed the effect of deletion of threonine at position 49. This dramati-
cally distorts the arrangement of its iron-sulfur cluster since it has a direct effect on
cysteine at position 46, which ligates one of the iron atoms. Our computations show
that the sterical effect of this deletion leads to a contribution of at least 50mV to the
lower redox potential due to electronic effects on the iron-sulfur cluster. Therefore,
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we are able to estimate this contribution from that of the remaining protein. For
our research aiming at a systemic evaluation of amino acid exchange influences on
the redox potential of Adx we came across a publication of Zhou [56]. They used a
simplified sphere model for protein and introduced the idea of setting dipole direc-
tions of amino acids in relation to the redox potential. This approximation is valid
as long as the contributions from the iron-sulfur cluster remain largely unchanged
upon mutation of the protein. The influence on the redox potential is most distinct
when a buried amino acid in close distance to the iron-sulfur cluster is changed. Also
the direction of its electric dipole plays a role. An increase of the redox potential
should be seen if the dipole vector points towards the iron-sulfur cluster, whereas
a decrease is expected if it points away. Perpendicular dipole vectors should only
show marginal effects. Based on this we suggested two mutations at position 43
with opposite effects that still awaits experimental validation at present.
Before that I tried an attempt to correlate experimentally derived redox potential
with computed ones. The goal was (like in chapter 5) to implement a systematic
evaluation that could estimate the influence of exchanging amino acids in bovine
Adx(4-108) WT molecules on the reduction potential. The influence could be mea-
sured in deviation from a normalized computed redox potential in relation to the
real experimental values. Lowering the redox potential would improve the perfor-
mance of Adx in terms of e.g. electron transfer rate. Experimentally derived values
for reduction potentials were collected from the excellent review from Ewen et al.
in 2011 [113]. Table 7.1 lists the mutations we took to computationally derive redox
potentials. Here the terms in brackets account for length of molecule and positions
of mutations (e.g. Adx(1-128/D76E) denotes full length Adx with an amino acid
exchange at position 76 where D (aspartic acid) is exchanged by E (glutamic acid)).
Starting from the crystal structure of wild type bovine Adx (pdb entry 1AYF) we
Adx(1-112) Adx(1-128/H56T) Adx(1-128/T49Y) Adx(4-108)
Adx(1-112/S112W) Adx(1-128/K6E) Adx(1-128/T54A) Adx(4-108/R14A)
Adx(1-112/Y82F/S112W) Adx(1-128/K6E/K22Q/K24Q) Adx(1-128/T54S) Adx(4-108/R14E)
Adx(1-112/Y82L/S112W) Adx(1-128/K6E/K22Q/K24Q/K98E) Adx(1-128/T71E) Adx(4-108A)
Adx(1-112/Y82S/S112W) Adx(1-128/K6E/K98E) Adx(1-128/T71V) Adx(4-108K)
Adx(1-128) Adx(1-128/K98E) Adx(1-128/Y82F) Adx(4-108S)
Adx(1-128/D76E) Adx(1-128/T49A) Adx(1-128/Y82L) Adx(4-108W)
Adx(1-128/H56Q) Adx(1-128/T49L) Adx(1-128/Y82S) Adx(4-114)
Adx(1-128/H56R) Adx(1-128/T49S) Adx(4-107) Adx(4-128)
Table 7.1: Overview of the different modeled Adx mutations. Terms in brackets ac-
count for length of molecule and positions of mutations (e.g. Adx(1-128/D76E) denotes
full length Adx with an amino acid exchange at position 76 where D (aspartic acid) is
exchanged by E (glutamic acid)).
built homology models with the SWISS-MODEL [119, 187, 120, 188] homology mod-
eling server according to the mutations listed in table 7.1. To relax tensions and get
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rid of other sterical discrepancies we simulated each of the Adx mutant in a water
bath at constant temperature and pressure for about 1 ns in TIP3P water [189]
(relaxation). Charges for the iron-sulfur clusters were taken from a prior publica-
tion from Shakya et al [190]. The subsequent computation of the redox potential
with the APBS program, however, did not produce reasonable values for further
use. Attempts to change the order of relaxation and building of homology models
did not have an influence on the quality of the results. The two approaches with
changing order were as follows. First relax the wild type, mutate it and do an energy
minimization and calculate the redox potential. Second, mutate the wild type and
relax it afterwards. The failure may be due to the lack of crystal structures for the
different mutants. Also the missing information on the conformational change of the
[Fe2S2] center upon reduction is probably a big issue. Poisson-Boltzmann theory re-
quires the accurate three-dimensional structure representation of both the oxidized
as well as the reduced Adx in solution, along with appropriate assignment of atomic
charges and protonation states for each amino acid [111, 115]. The problem with
measuring the effect of conformational changes needs to be computed by quantum
mechanical methods like DFT, which are very time demanding and inappropriate
for the size as well as the amount of molecules. A detailed analysis of the set of
Adx mutants (table 7.1) revealed that the redox potential strongly correlates with
the accessible surface area. This means that exchanging a big amino acid with a
small one should change the redox potential massively. But only on certain positions
in the Adx which then are the important contact interfaces (e.g.Y82S, position 82
plays an important role). Since there was seen a big decrease in redox potential for
the exchange of proline to lysine at position 108 another exchange was testet besides
the ones at position 82. The proposed candidates for new mutations for lowering the
redox potential are given in table 7.2. The terms in brackets account for length of
the molecule and positions of mutations (e.g. Adx(4-108/P108R) denotes a trimmed
version of Adx (from amino acid at position 4 to 108) with an amino acid exchange
at position 108 where P (proline) is exchanged by R (Arginine)). The redox poten-
tials are given in mV together with the standard deviation, which is rather high.
Exchange of tyrosine at position 82 with serine should lower the redox potential due
to changes in terms of size. Exchange with asparagine could lead into an internal
salt bridge with the proposed arginine at position 108. Both changes at position
82 were conjugated with changes at position 108 to arginine and lysine. However,
results show that the changes only have minor influences and our propositions did
not have the desired effects. In addition to that, the constructs of these mutants in
the wetlab were rather unstable. proline at position 108 is almost indispensable as
stabilizing residue.
This work dealt with the optimization of protein-protein and protein-ligand inter-
actions trying to add an other piece to the puzzle of decrypting the way for the
biotechnological application of CYP P450 redox systems. For the case of Adx my
focus shifted more and more in the direction of fundamental research. Meaning to
investigate why and how the redox potential changes upon introducing other amino
acids into the structure. Two attempts were undertaken that failed to explain this.
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Mutation Avg redox potential[mV] SD
Adx(4-108) -324.62 2.45
Adx(4-108/P108R) -319.03 21.83
Adx(4-108/Y82S/P108R) -314.36 2.63
Adx(4-108/Y82D/P108R) -372.99 27.24
Adx(4-108/Y82S/P108K) -336.44 12.36
Adx(4-108/Y82D/P108K) -341.88 24.04
Table 7.2: Average redox potentials from newly proposed Adx mutations. In relation to
the shorter wild type Adx4-108 all others are not noteworthy better or worse than others
from [113]. Also the standard deviation is very high. Terms in brackets account for length
of molecule and positions of mutations (e.g. Adx(4-108/P108R) denotes a trimmed version
of Adx (from amino acid at position 4 to 108) with an amino acid exchange at position
108 where P (proline) is exchanged by R (arginine)).
The validation of another theory that could explain this is still ongoing. Theoret-
ical groundwork has been done and suffices experimental validation (see chapter
5). Building up on this one could be able to predict results of exchanges of amino
acids. Furthermore this could be extended to other ferre- or flavodoxins affecting
other CYP P450 redox systems. Besides the focus on Adx and the improvement
of interaction to CYP P450s a proof for efficiency could be delivered for a fusion
of a flavodoxin and a reductase (chapter 6). The kind of linker construct was im-
portant for keeping the two proteins separate over a certain distance that allowed
for regenerating the system for following oxidations and reductions of the heme
centers and electron donors, NAD(P)H respectively. Since there were no crystal
structures of fused systems from nature available, a complete picture about their
behaviour in solution (with e.g. MD simulations) cannot be delivered yet. How-
ever, this concept also could be applied to Adx or Etp1 with a given reductase for
further tuning the electron transport efficiency. Protein engineering of CYP106A2
lead to a substantial success in steering the synthesis of progesterone to alternatively
hydroxylated progesterone products, that are important for diverse pharmaceutical
applications. In particular, using docking of substrates into the available crystal
structure and likewise into homology models of rationally designed mutants, proved
to be a valuable tool to complement experimental work. Furthermore, molecular dy-
namics simulations revealed that reorientation of primary hydroxylation products
inside the binding pocket occurs on a fast time scale. This prompted further exper-
imental studies regarding the electron transport towards the cytochrome, which are
still ongoing.
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